1
|
Batchu S, Diaz MJ, Patel A, Reddy A, Lucke-Wold B. Transcriptome-Derived Ligand-Receptor Interactome of Major PitNET Subgroups. J Neurol Surg B Skull Base 2024; 85:340-346. [PMID: 38966297 PMCID: PMC11221903 DOI: 10.1055/a-2088-6594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2022] [Accepted: 05/03/2023] [Indexed: 07/06/2024] Open
Abstract
Introduction Pituitary neuroendocrine tumors (PitNETs) are rare skull base tumors which can impart significant disability owing to their locally invasive potential. To date, the gamut of PitNET subtypes remains ill-understood at the ligand-receptor (LR) interactome level, potentially limiting therapeutic options. Here, we present findings from in silico analysis of LR complexes formed by PitNETs with clinical presentations of acromegaly, Cushing's disease, high prolactin production, and without symptoms of hormone hypersecretion. Methods Previously published PitNET gene expression data was acquired from ArrayExpress. These data represented all secretion types. LR interactions were analyzed via a crosstalk score approach. Results Cortisol (CORT) ligand was significantly involved in tumor-to-tumor signaling across all PitNET subtypes but prolactinomas, which evidenced active CORT depletion. Likewise, CCL25 ligand was implicated in 20% of the top LR complex interactions along the tumor-to-stroma signaling axis, but silent PitNETs reported unique depletion of the CCL25 ligand. Along the stroma-to-tumor signaling axis, all clinical PitNET subtypes enriched stromal vasoactive intestinal polypeptide ligand interactions with tumor secretin receptor. All clinical PitNET subtypes enriched stromal DEFB103B (human β-defensin 103B) ligand interactions with stromal chemokine receptors along the stroma-to-stroma signaling axis. In PitNETs causing Cushing's disease, immune checkpoint ligand CD274 reported high stromal expression, and prolactinomas reported low stromal expression. Moreover, prolactinomas evidenced distinctly high stromal expression of immune-exhausted T cell response marker IL10RA compared with other clinical subtypes. Conclusion Relative crosstalk score analysis revealed a great diversity of LR complex interactions across clinical PitNET subtypes and between solid tumor compartments. More data are needed to validate these findings and exact clinical importance.
Collapse
Affiliation(s)
- Sai Batchu
- Cooper Medical School, Rowan University, Camden, New Jersey, United States
| | - Michael Joseph Diaz
- College of Medicine, University of Florida, Gainesville, Florida, United States
| | - Aashay Patel
- College of Medicine, University of Florida, Gainesville, Florida, United States
| | - Akshay Reddy
- College of Medicine, University of Florida, Gainesville, Florida, United States
| | - Brandon Lucke-Wold
- Department of Neurosurgery, University of Florida, Gainesville, Florida, United States
| |
Collapse
|
2
|
Li H, Xie J, Song J, Jin C, Xin H, Pan X, Ke J, Yuan Y, Shen H, Ning G. CRCS: An automatic image processing pipeline for hormone level analysis of Cushing's disease. Methods 2024; 222:28-40. [PMID: 38159688 DOI: 10.1016/j.ymeth.2023.12.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Revised: 12/01/2023] [Accepted: 12/25/2023] [Indexed: 01/03/2024] Open
Abstract
Due to the abnormal secretion of adreno-cortico-tropic-hormone (ACTH) by tumors, Cushing's disease leads to hypercortisonemia, a precursor to a series of metabolic disorders and serious complications. Cushing's disease has high recurrence rate, short recurrence time and undiscovered recurrence reason after surgical resection. Qualitative or quantitative automatic image analysis of histology images can potentially in providing insights into Cushing's disease, but still no software has been available to the best of our knowledge. In this study, we propose a quantitative image analysis-based pipeline CRCS, which aims to explore the relationship between the expression level of ACTH in normal cell tissues adjacent to tumor cells and the postoperative prognosis of patients. CRCS mainly consists of image-level clustering, cluster-level multi-modal image registration, patch-level image classification and pixel-level image segmentation on the whole slide imaging (WSI). On both image registration and classification tasks, our method CRCS achieves state-of-the-art performance compared to recently published methods on our collected benchmark dataset. In addition, CRCS achieves an accuracy of 0.83 for postoperative prognosis of 12 cases. CRCS demonstrates great potential for instrumenting automatic diagnosis and treatment for Cushing's disease.
Collapse
Affiliation(s)
- Haiyue Li
- Institute of Image Processing and Pattern Recognition, Shanghai Jiao Tong University, and Key Laboratory of System Control and Information Processing, Ministry of Education of China, Shanghai 200240, China
| | - Jing Xie
- Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, 197 Ruijin 2nd Road, Shanghai 200025, China
| | - Jialin Song
- The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiao Tong University, Xi'an 710049, China
| | - Cheng Jin
- Medical Robot Research Institute, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China
| | - Hongyi Xin
- University of Michigan - Shanghai Jiao Tong University Joint Institute Shanghai Jiao Tong University, Shanghai 200240, China
| | - Xiaoyong Pan
- Institute of Image Processing and Pattern Recognition, Shanghai Jiao Tong University, and Key Laboratory of System Control and Information Processing, Ministry of Education of China, Shanghai 200240, China
| | - Jing Ke
- Department of Computer Science and Engineering, Shanghai Jiao Tong University, Shanghai 200240, China
| | - Ye Yuan
- Institute of Image Processing and Pattern Recognition, Shanghai Jiao Tong University, and Key Laboratory of System Control and Information Processing, Ministry of Education of China, Shanghai 200240, China
| | - Hongbin Shen
- Institute of Image Processing and Pattern Recognition, Shanghai Jiao Tong University, and Key Laboratory of System Control and Information Processing, Ministry of Education of China, Shanghai 200240, China.
| | - Guang Ning
- State Key Laboratory of Medical Genomes, National Clinical Research Center for Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Laboratory of Endocrinology and Metabolism, Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China.
| |
Collapse
|
3
|
Mallick S, Chakrabarti J, Eschbacher J, Moraitis AG, Greenstein AE, Churko J, Pond KW, Livolsi A, Thorne CA, Little AS, Yuen KCJ, Zavros Y. Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators. Transl Res 2023; 256:56-72. [PMID: 36640905 PMCID: PMC11345864 DOI: 10.1016/j.trsl.2023.01.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Revised: 12/12/2022] [Accepted: 01/04/2023] [Indexed: 01/13/2023]
Abstract
Cushing's disease (CD) is a serious endocrine disorder attributed to an adrenocorticotropic hormone (ACTH)-secreting pituitary neuroendocrine tumor (PitNET) that that subsequently leads to chronic hypercortisolemia. PitNET regression has been reported following treatment with the investigational selective glucocorticoid receptor (GR) modulator relacorilant, but the mechanisms behind that effect remain unknown. Human PitNET organoid models were generated from induced human pluripotent stem cells (iPSCs) or fresh tissue obtained from CD patient PitNETs (hPITOs). Genetically engineered iPSC derived organoids were used to model the development of corticotroph PitNETs expressing USP48 (iPSCUSP48) or USP8 (iPSCUSP8) somatic mutations. Organoids were treated with the GR antagonist mifepristone or the GR modulator relacorilant with or without somatostatin receptor (SSTR) agonists pasireotide or octreotide. In iPSCUSP48 and iPSCUSP8 cultures, mifepristone induced a predominant expression of SSTR2 with a concomitant increase in ACTH secretion and tumor cell proliferation. Relacorilant predominantly induced SSTR5 expression and tumor cell apoptosis with minimal ACTH induction. Hedgehog signaling mediated the induction of SSTR2 and SSTR5 in response to mifepristone and relacorilant. Relacorilant sensitized PitNET organoid responsiveness to pasireotide. Therefore, our study identified the potential therapeutic use of relacorilant in combination with somatostatin analogs and demonstrated the advantages of relacorilant over mifepristone, supporting its further development for use in the treatment of Cushing's disease patients.
Collapse
Affiliation(s)
- Saptarshi Mallick
- Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, Arizona
| | - Jayati Chakrabarti
- Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, Arizona
| | - Jennifer Eschbacher
- Department of Neuropathology, Barrow Neurological Institute, Phoenix, Arizona
| | | | | | - Jared Churko
- Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, Arizona
| | - Kelvin W Pond
- Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, Arizona
| | | | - Curtis A Thorne
- Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, Arizona
| | - Andrew S Little
- Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona
| | - Kevin C J Yuen
- Department of Neuroendocrinology, Barrow Neurological Institute, Phoenix, Arizona
| | - Yana Zavros
- Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, Arizona.
| |
Collapse
|
4
|
Chakrabarti J, Pandey R, Churko JM, Eschbacher J, Mallick S, Chen Y, Hermes B, Mallick P, Stansfield BN, Pond KW, Thorne CA, Yuen KCJ, Little AS, Zavros Y. Development of Human Pituitary Neuroendocrine Tumor Organoids to Facilitate Effective Targeted Treatments of Cushing's Disease. Cells 2022; 11:3344. [PMID: 36359740 PMCID: PMC9659185 DOI: 10.3390/cells11213344] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Revised: 10/19/2022] [Accepted: 10/19/2022] [Indexed: 08/25/2023] Open
Abstract
(1) Background: Cushing's disease (CD) is a serious endocrine disorder caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary neuroendocrine tumor (PitNET) that stimulates the adrenal glands to overproduce cortisol. Chronic exposure to excess cortisol has detrimental effects on health, including increased stroke rates, diabetes, obesity, cognitive impairment, anxiety, depression, and death. The first-line treatment for CD is pituitary surgery. Current surgical remission rates reported in only 56% of patients depending on several criteria. The lack of specificity, poor tolerability, and low efficacy of the subsequent second-line medical therapies make CD a medical therapeutic challenge. One major limitation that hinders the development of specific medical therapies is the lack of relevant human model systems that recapitulate the cellular composition of PitNET microenvironment. (2) Methods: human pituitary tumor tissue was harvested during transsphenoidal surgery from CD patients to generate organoids (hPITOs). (3) Results: hPITOs generated from corticotroph, lactotroph, gonadotroph, and somatotroph tumors exhibited morphological diversity among the organoid lines between individual patients and amongst subtypes. The similarity in cell lineages between the organoid line and the patient's tumor was validated by comparing the neuropathology report to the expression pattern of PitNET specific markers, using spectral flow cytometry and exome sequencing. A high-throughput drug screen demonstrated patient-specific drug responses of hPITOs amongst each tumor subtype. Generation of induced pluripotent stem cells (iPSCs) from a CD patient carrying germline mutation CDH23 exhibited dysregulated cell lineage commitment. (4) Conclusions: The human pituitary neuroendocrine tumor organoids represent a novel approach in how we model complex pathologies in CD patients, which will enable effective personalized medicine for these patients.
Collapse
Affiliation(s)
- Jayati Chakrabarti
- Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, AZ 85721, USA
| | - Ritu Pandey
- Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, AZ 85721, USA
- Center for Biomedical Informatics and Biostatistics, University of Arizona Health Sciences, Tucson, AZ 85721, USA
| | - Jared M. Churko
- Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, AZ 85721, USA
| | - Jennifer Eschbacher
- Department of Neuropathology, Barrow Neurological Institute, Phoenix, AZ 85013, USA
| | - Saptarshi Mallick
- Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, AZ 85721, USA
| | - Yuliang Chen
- University of Arizona Cancer Center Bioinformatics Core, Tucson, AZ 85721, USA
| | - Beth Hermes
- Department of Neuropathology, Barrow Neurological Institute, Phoenix, AZ 85013, USA
| | - Palash Mallick
- Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, AZ 85721, USA
| | - Ben N. Stansfield
- Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, AZ 85721, USA
| | - Kelvin W. Pond
- Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, AZ 85721, USA
| | - Curtis A. Thorne
- Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, AZ 85721, USA
| | - Kevin C. J. Yuen
- Department of Neuroendocrinology, Barrow Neurological Institute, Phoenix, AZ 85013, USA
| | - Andrew S. Little
- Department of Neurosurgery, Barrow Neurological Institute, Phoenix, AZ 85013, USA
| | - Yana Zavros
- Department of Cellular and Molecular Medicine, University of Arizona College of Medicine, Tucson, AZ 85721, USA
| |
Collapse
|
5
|
Moreno-Moreno P, Ibáñez-Costa A, Venegas-Moreno E, Fuentes-Fayos AC, Alhambra-Expósito MR, Fajardo-Montañana C, García-Martínez A, Dios E, Vázquez-Borrego MC, Remón-Ruiz P, Cámara R, Lamas C, Carlos Padillo-Cuenca J, Solivera J, Cano DA, Gahete MD, Herrera-Martínez AD, Picó A, Soto-Moreno A, Gálvez-Moreno MÁ, Castaño JP, Luque RM. Integrative Clinical, Radiological, and Molecular Analysis for Predicting Remission and Recurrence of Cushing Disease. J Clin Endocrinol Metab 2022; 107:e2938-e2951. [PMID: 35312002 DOI: 10.1210/clinem/dgac172] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2021] [Indexed: 11/19/2022]
Abstract
CONTEXT Adrenocorticotropin (ACTH)-secreting pituitary tumors (ACTHomas) are associated with severe comorbidities and increased mortality. Current treatments mainly focus on remission and prevention of persistent disease and recurrence. However, there are still no useful biomarkers to accurately predict the clinical outcome after surgery, long-term remission, or disease relapse. OBJECTIVES This work aimed to identify clinical, biochemical, and molecular markers for predicting long-term clinical outcome and remission in ACTHomas. METHODS A retrospective multicenter study was performed with 60 ACTHomas patients diagnosed between 2004 and 2018 with at least 2 years' follow-up. Clinical/biochemical variables were evaluated yearly. Molecular expression profile of the somatostatin/ghrelin/dopamine regulatory systems components and of key pituitary factors and proliferation markers were evaluated in tumor samples after the first surgery. RESULTS Clinical variables including tumor size, time until diagnosis/first surgery, serum prolactin, and postsurgery cortisol levels were associated with tumor remission and relapsed disease. The molecular markers analyzed were distinctly expressed in ACTHomas, with some components (ie, SSTR1, CRHR1, and MKI67) showing instructive associations with recurrence and/or remission. Notably, an integrative model including selected clinical variables (tumor size/postsurgery serum cortisol), and molecular markers (SSTR1/CRHR1) can accurately predict the clinical evolution and remission of patients with ACTHomas, generating a receiver operating characteristic curve with an area under the curve of 1 (P < .001). CONCLUSION This study demonstrates that the combination of a set of clinical and molecular biomarkers in ACTHomas is able to accurately predict the clinical evolution and remission of patients. Consequently, the postsurgery molecular profile represents a valuable tool for clinical evaluation and follow-up of patients with ACTHomas.
Collapse
Affiliation(s)
- Paloma Moreno-Moreno
- Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain
- Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain
- Service of Endocrinology and Nutrition, IMIBIC, HURS, 14004 Cordoba, Spain
| | - Alejandro Ibáñez-Costa
- Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain
- Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain
- Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain
- CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 14004 Cordoba, Spain
| | - Eva Venegas-Moreno
- Unidad de Gestión de Endocrinología y Nutrición. Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Sevilla, Spain
| | - Antonio C Fuentes-Fayos
- Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain
- Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain
- Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain
- CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 14004 Cordoba, Spain
| | - María R Alhambra-Expósito
- Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain
- Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain
- Service of Endocrinology and Nutrition, IMIBIC, HURS, 14004 Cordoba, Spain
| | - Carmen Fajardo-Montañana
- Department of Endocrinology, Hospital Universitario de La Ribera, Alzira, 46600, Valencia, Spain
| | - Araceli García-Martínez
- Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain
- Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain
- Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain
| | - Elena Dios
- Unidad de Gestión de Endocrinología y Nutrición. Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Sevilla, Spain
| | - Mari C Vázquez-Borrego
- Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain
- Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain
- Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain
- CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 14004 Cordoba, Spain
| | - Pablo Remón-Ruiz
- Unidad de Gestión de Endocrinología y Nutrición. Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Sevilla, Spain
| | - Rosa Cámara
- Department of Endocrinology and Nutrition, Polytechnic University Hospital La Fe, 46026, Valencia, Spain
| | - Cristina Lamas
- Department of Endocrinology and Nutrition, Albacete University Hospital, 02006, Albacete, Spain
| | - José Carlos Padillo-Cuenca
- Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain
- Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain
- Service of Endocrinology and Nutrition, IMIBIC, HURS, 14004 Cordoba, Spain
| | | | - David A Cano
- Unidad de Gestión de Endocrinología y Nutrición. Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Sevilla, Spain
| | - Manuel D Gahete
- Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain
- Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain
- Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain
- CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 14004 Cordoba, Spain
| | - Aura D Herrera-Martínez
- Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain
- Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain
- Service of Endocrinology and Nutrition, IMIBIC, HURS, 14004 Cordoba, Spain
| | - Antonio Picó
- Department of Endocrinology and Nutrition, Alicante General University Hospital. Institute for Health and Biomedical Research (ISABIAL). University Miguel Hernandez, CIBER Rare Diseases, 03010, Alicante, Spain
| | - Alfonso Soto-Moreno
- Unidad de Gestión de Endocrinología y Nutrición. Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Sevilla, Spain
| | - María Ángeles Gálvez-Moreno
- Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain
- Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain
- Service of Endocrinology and Nutrition, IMIBIC, HURS, 14004 Cordoba, Spain
| | - Justo P Castaño
- Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain
- Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain
- Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain
- CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 14004 Cordoba, Spain
| | - Raúl M Luque
- Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain
- Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain
- Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain
- CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 14004 Cordoba, Spain
| |
Collapse
|
6
|
Aydin B, Yildirim E, Erdogan O, Arga KY, Yilmaz BK, Bozkurt SU, Bayrakli F, Turanli B. Past, Present, and Future of Therapies for Pituitary Neuroendocrine Tumors: Need for Omics and Drug Repositioning Guidance. OMICS : A JOURNAL OF INTEGRATIVE BIOLOGY 2022; 26:115-129. [PMID: 35172108 DOI: 10.1089/omi.2021.0221] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Innovation roadmaps are important, because they encourage the actors in an innovation ecosystem to creatively imagine multiple possible science future(s), while anticipating the prospects and challenges on the innovation trajectory. In this overarching context, this expert review highlights the present unmet need for therapeutic innovations for pituitary neuroendocrine tumors (PitNETs), also known as pituitary adenomas. Although there are many drugs used in practice to treat PitNETs, many of these drugs can have negative side effects and show highly variable outcomes in terms of overall recovery. Building innovation roadmaps for PitNETs' treatments can allow incorporation of systems biology approaches to bring about insights at multiple levels of cell biology, from genes to proteins to metabolites. Using the systems biology techniques, it will then be possible to offer potential therapeutic strategies for the convergence of preventive approaches and patient-centered disease treatment. Here, we first provide a comprehensive overview of the molecular subtypes of PitNETs and therapeutics for these tumors from the past to the present. We then discuss examples of clinical trials and drug repositioning studies and how multi-omics studies can help in discovery and rational development of new therapeutics for PitNETs. Finally, this expert review offers new public health and personalized medicine approaches on cases that are refractory to conventional treatment or recur despite currently used surgical and/or drug therapy.
Collapse
Affiliation(s)
- Busra Aydin
- Department of Bioengineering, Faculty of Engineering, Marmara University, Istanbul, Turkey
| | - Esra Yildirim
- Department of Bioengineering, Faculty of Engineering, Marmara University, Istanbul, Turkey
| | - Onur Erdogan
- Department of Neurosurgery, School of Medicine, Marmara University, Istanbul, Turkey
| | - Kazim Yalcin Arga
- Department of Bioengineering, Faculty of Engineering, Marmara University, Istanbul, Turkey
- Genetic and Metabolic Diseases Research and Investigation Center, Marmara University, Istanbul, Turkey
| | - Betul Karademir Yilmaz
- Genetic and Metabolic Diseases Research and Investigation Center, Marmara University, Istanbul, Turkey
- Department of Biochemistry and School of Medicine, Marmara University, Istanbul, Turkey
| | - Suheyla Uyar Bozkurt
- Department of Medical Pathology, School of Medicine, Marmara University, Istanbul, Turkey
| | - Fatih Bayrakli
- Department of Neurosurgery, School of Medicine, Marmara University, Istanbul, Turkey
- Institute of Neurological Sciences, Marmara University, Istanbul, Turkey
| | - Beste Turanli
- Department of Bioengineering, Faculty of Engineering, Marmara University, Istanbul, Turkey
| |
Collapse
|
7
|
De Ravin E, Phan HAT, Harmsen S, Cho SS, Teng CW, Petersson EJ, White C, Galban EM, Hess R, Lee JYK. Somatostatin Receptor as a Molecular Imaging Target in Human and Canine Cushing Disease. World Neurosurg 2021; 149:94-102. [PMID: 33601082 DOI: 10.1016/j.wneu.2021.02.034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Revised: 02/07/2021] [Accepted: 02/08/2021] [Indexed: 11/25/2022]
Abstract
OBJECTIVES Fluorescence-guided surgery may improve completeness of resection in transsphenoidal surgery for Cushing disease (CD) by enabling visualization of residual tumor tissue at the margins. In this review we discuss somatostatin receptors (SSTRs) as targets for fluorescence-guided surgery and overview existing SSTR-specific imaging agents. We also compare SSTR expression in normal pituitary and corticotrophinoma tissues from human and canine CD patients to assess canines as a translational model for CD. METHODS A PubMed literature search was conducted for publications containing the terms canine, somatostatin receptor, Cushing's disease, and corticotroph adenoma. SSTR expression data from each study was documented as the presence or absence of expression or, when possible, the number of tumors expressing a given SSTR subtype within a group of tumors being studied. Studies that used reverse transcription polymerase chain reaction to quantify SSTR expression were selected for additional comparative analysis. RESULTS SSTR5 is strongly expressed in human corticotroph adenomas and weakly expressed in surrounding pituitary parenchyma, a pattern not conclusively observed in canine patients. SSTR2 mRNA expression is similar in human normal pituitary and corticotrophinoma cells but may be significantly higher in canine normal pituitary tissue than in corticotroph tumoral tissue. Limited data were available on SSTR subtypes 1, 3, and 4. CONCLUSIONS Further studies must fill the knowledge gaps related to species-specific SSTR expression, so using canine CD as a translational model may be premature. We do conclude that the expression profile of SSTR5 (i.e., high local expression in pituitary adenomas relative to normal surrounding tissues) makes SSTR5 a promising molecular target for FGS.
Collapse
Affiliation(s)
- Emma De Ravin
- Department of Neurosurgery at the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Hoang Anh T Phan
- Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Stefan Harmsen
- Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Steve S Cho
- Department of Neurosurgery at the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Clare W Teng
- Department of Neurosurgery at the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - E James Petersson
- Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Caitlin White
- Department of Endocrinology at the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Evelyn M Galban
- Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Rebecka Hess
- Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - John Y K Lee
- Department of Neurosurgery at the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
| |
Collapse
|
8
|
Wu Z, Gu W. Autophagy and Pituitary Adenoma. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2020; 1207:183-194. [PMID: 32671747 DOI: 10.1007/978-981-15-4272-5_12] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Pituitary adenomas (PAs) are common, benign intracranial tumors that are usually effectively controlled with surgery, pharmacotherapy or radiotherapy. Some PAs against which conventional treatment is ineffective are great clinical challenges at present. Autophagy is a widespread physiological process in cells. Through autophagy, cells can degrade damaged or redundant proteins and organelles and achieve the recycling of intracellular substances to maintain the homeostasis of the intracellular environment. An increasing number of studies have demonstrated the importance of autophagy in tumor therapy. Both radiotherapy and chemotherapy can induce autophagy, which plays different roles in the course of therapy. In recent years, there has been growing interest in the role of autophagy during the treatment of PAs. This chapter reviews the recent progress of research on autophagy in PA and the autophagic mechanisms in the treatment of PA.
Collapse
Affiliation(s)
- Zhebao Wu
- Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
| | - Weiting Gu
- Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| |
Collapse
|
9
|
Kannankeril J, Carroll T, Findling JW, Javorsky B, Gunsolus IL, Phillips J, Raff H. Prospective Evaluation of Late-Night Salivary Cortisol and Cortisone by EIA and LC-MS/MS in Suspected Cushing Syndrome. J Endocr Soc 2020; 4:bvaa107. [PMID: 32935666 PMCID: PMC7480956 DOI: 10.1210/jendso/bvaa107] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Accepted: 07/20/2020] [Indexed: 01/15/2023] Open
Abstract
Context Late-night salivary cortisol (LNSC) measured by enzyme immunoassay (EIA-F) is a first-line screening test for Cushing syndrome (CS) with a reported sensitivity and specificity of >90%. However, liquid chromatography-tandem mass spectrometry, validated to measure salivary cortisol (LCMS-F) and cortisone (LCMS-E), has been proposed to be superior diagnostically. Objective, Setting, and Main Outcome Measures Prospectively evaluate the diagnostic performance of EIA-F, LCMS-F, and LCMS-E in 1453 consecutive late-night saliva samples from 705 patients with suspected CS. Design Patients grouped by the presence or absence of at least one elevated salivary steroid result and then subdivided by diagnosis. Results We identified 283 patients with at least one elevated salivary result; 45 had an established diagnosis of neoplastic hypercortisolism (CS) for which EIA-F had a very high sensitivity (97.5%). LCMS-F and LCMS-E had lower sensitivity but higher specificity than EIA-F. EIA-F had poor sensitivity (31.3%) for adrenocorticotropic hormone (ACTH)-independent CS (5 patients with at least 1 and 11 without any elevated salivary result). In patients with Cushing disease (CD), most nonelevated LCMS-F results were in patients with persistent/recurrent CD; their EIA-F levels were lower than in patients with newly diagnosed CD. Conclusions Since the majority of patients with ≥1 elevated late-night salivary cortisol or cortisone result did not have CS, a single elevated level has poor specificity and positive predictive value. LNSC measured by EIA is a sensitive test for ACTH-dependent Cushing syndrome but not for ACTH-independent CS. We suggest that neither LCMS-F nor LCMS-E improves the sensitivity of late-night EIA-F for CS.
Collapse
Affiliation(s)
- Joshua Kannankeril
- Division of Endocrinology and Molecular Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
| | - Ty Carroll
- Endocrinology Center and Clinics, Medical College of Wisconsin, Milwaukee, Wisconsin
| | - James W Findling
- Endocrinology Center and Clinics, Medical College of Wisconsin, Milwaukee, Wisconsin
| | - Bradley Javorsky
- Endocrinology Center and Clinics, Medical College of Wisconsin, Milwaukee, Wisconsin
| | - Ian L Gunsolus
- Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin
| | - Jonathan Phillips
- Endocrine Research Laboratory, Aurora St. Luke's Medical Center, Advocate Aurora Research Institute, Milwaukee, Wisconsin
| | - Hershel Raff
- Division of Endocrinology and Molecular Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.,Endocrine Research Laboratory, Aurora St. Luke's Medical Center, Advocate Aurora Research Institute, Milwaukee, Wisconsin
| |
Collapse
|
10
|
Lacroix A, Gu F, Schopohl J, Kandra A, Pedroncelli AM, Jin L, Pivonello R. Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study. Pituitary 2020; 23:203-211. [PMID: 31875276 PMCID: PMC7181422 DOI: 10.1007/s11102-019-01021-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
PURPOSE In the multinational, randomized, double-blind, Phase 3 B2305 study of patients with Cushing's disease (CD; ClinicalTrials.gov identifier NCT00434148), pasireotide substantially decreased urinary-free cortisol (UFC) levels, decreased mean corticotroph tumor volume, and improved clinical signs of disease. The current post hoc analysis further assesses the effects of pasireotide on corticotroph pituitary tumor volume. METHODS Patients enrolled in the B2305 study had persistent or recurrent CD or newly diagnosed CD but were not surgical candidates. Enrollees were randomized to receive subcutaneous pasireotide, either 600-μg or 900-μg twice daily. Tumor volume was assessed independently at months 6 and 12 by 2 blinded radiologists and compared with baseline value and UFC response. RESULTS Of 162 patients enrolled in the trial, 53 had measurable tumor volume data and were included in the post hoc analysis. Reductions in tumor volume were both dose and time dependent. Tumor volume reduction was more frequently observed at month 6 in the 900-μg group (75%) than in the 600-μg group (44%). Similarly, at month 12 (n = 32), tumor volume reduction was observed more frequently in the 900-µg group (89%) than in the 600-µg group (50%). Control of UFC levels was not required for reduction of tumor volume. No relationship was noted between baseline tumor size and change in tumor size. CONCLUSIONS Measurable decreases in pituitary tumor volume were observed in a large proportion of patients with CD and measurable tumor volume who were enrolled in the trial and treated with subcutaneous pasireotide; this decrease was not correlated with UFC control. CLINICALTRIALS. GOV IDENTIFIER NCT00434148.
Collapse
Affiliation(s)
- André Lacroix
- Division of Endocrinology, Department of Medicine, Centre hospitalier de l'Université de Montréal (CHUM), 900, rue Saint-Denis, Room R08-474, Montréal, QC, H2X 0A9, Canada.
| | - Feng Gu
- Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Beijing, China
| | - Jochen Schopohl
- Medizinsche Klinik IV, Ludwig-Maximilians Universität München, Munich, Germany
| | | | | | - Lixian Jin
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | - Rosario Pivonello
- Dipartimento Di Medicina Clinica E Chirurgia, Sezione Di Endocrinologia, Università Federico II Di Napoli, Naples, Italy
| |
Collapse
|
11
|
Boyce AM, Collins MT. Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation. Endocr Rev 2020; 41:5610851. [PMID: 31673695 PMCID: PMC7127130 DOI: 10.1210/endrev/bnz011] [Citation(s) in RCA: 76] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Accepted: 10/29/2019] [Indexed: 12/14/2022]
Abstract
Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) is a rare disorder of striking complexity. It arises from somatic, gain-of-function mutations in GNAS, leading to mosaic Gα s activation and inappropriate production of intracellular cyclic adenosine monophosphate (cAMP). The clinical phenotype is largely determined by the location and extent of affected tissues, and the pathophysiological effects of Gα s activation within these tissues. In bone, Gα s activation results in impaired differentiation of skeletal stem cells, leading to discrete skeletal lesions prone to fracture, deformity, and pain. Extraskeletal manifestations include a variable combination of hyperpigmented macules and hyperfunctioning endocrinopathies. Distinctive age-related changes in disease development has key effects on histologic, radiographic, and clinical features. FD/MAS thus presents along a uniquely broad clinical spectrum, and the resulting challenges in diagnosis and management can be difficult for clinicians. This review presents FD/MAS in the context of a mosaic disorder of Gα s activation, providing an intellectual framework within which to understand, evaluate, and treat this interesting disease. It includes a comprehensive summary of current understanding of FD/MAS pathogenesis, and a detailed discussion of clinical presentation and management. Critical areas of unmet need are highlighted, including discussion of key challenges and potential solutions to advance research and clinical care in FD/MAS.
Collapse
Affiliation(s)
- Alison M Boyce
- Skeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland
| | - Michael T Collins
- Skeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland
| |
Collapse
|
12
|
Anokhin PK, Veretinskaya AG, Pavshintsev VV, Shamakina IY. [The effect of the dopamine D2 receptor agonist cabergoline on the content of catecholamines and expression of BDNF mRNA in the rat midbrain and hypothalamus]. Zh Nevrol Psikhiatr Im S S Korsakova 2019; 119:54-59. [PMID: 31851173 DOI: 10.17116/jnevro201911911154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
AIM To study an effect of cabergoline on dopamine and noradrenaline concentration and BDNF mRNA level in the rat midbrain and hypothalamus. MATERIAL AND METHODS Twenty adult male Wistar rats were used in a single treatment paradigm: animals of the treatment group (n=10) received cabergoline (i.p., 0.5 mg/kg) and the control group (n=10) received an equivalent volume of the solvent. Quantitative analysis for the dopamine (DA) and noradrenaline (NA) was carried out using high-performance liquid chromatography (HPLC) coupled with electrochemical detection. BDNF mRNA levels were studied using quantitative RT-PCR. RESULTS AND CONCLUSION Cabergoline significantly increases NA concentration in the midbrain 24 hours after injection: 639.2±64.5 ng/g in the treatment group versus 398.0±66.0 ng/g in the control group (p<0.05), while mean content of DA is not significantly changed (211.4±16.3 ng/g vs 169.7±54.6 ng/g, respectively). Cabergoline does not affect hypothalamic DA and NA levels. The drug increases BDNF mRNA levels by 2-times in the midbrain, but not in the hypothalamus, 24 hours after injection.
Collapse
Affiliation(s)
- P K Anokhin
- Nationa Research Center on Addiction - The Branch of Serbsky National Medical Research Centre for Psychiatry and Narcology, Moscow, Russia
| | - A G Veretinskaya
- Nationa Research Center on Addiction - The Branch of Serbsky National Medical Research Centre for Psychiatry and Narcology, Moscow, Russia
| | | | - I Yu Shamakina
- Nationa Research Center on Addiction - The Branch of Serbsky National Medical Research Centre for Psychiatry and Narcology, Moscow, Russia
| |
Collapse
|
13
|
Kemeny HR, Elsamadicy AA, Farber SH, Champion CD, Lorrey SJ, Chongsathidkiet P, Woroniecka KI, Cui X, Shen SH, Rhodin KE, Tsvankin V, Everitt J, Sanchez-Perez L, Healy P, McLendon RE, Codd PJ, Dunn IF, Fecci PE. Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. Clin Cancer Res 2019; 26:1141-1151. [PMID: 31744830 PMCID: PMC7809696 DOI: 10.1158/1078-0432.ccr-18-3486] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2018] [Revised: 10/02/2019] [Accepted: 11/15/2019] [Indexed: 11/16/2022]
Abstract
PURPOSE Although pituitary adenoma is classified as benign, Cushing disease is associated with significant morbidity due to the numerous sequelae of elevated cortisol levels. Successful therapy for Cushing disease remains elusive due to high rates of treatment-refractory recurrence. The frequent emergence of lymphocytic hypophysitis following checkpoint blockade for other cancers, as well as the expression of PD-L1 on pituitary adenomas, suggest a role for immunotherapy. EXPERIMENTAL DESIGN This study confirms PD-L1 expression on functioning pituitary adenomas and is the first to evaluate the efficacy of checkpoint blockade (anti-PD-L1) therapy in a preclinical model of Cushing disease. RESULTS Herein, treatment with anti-PD-L1 was successful in reducing adrenocorticotropic hormone plasma levels, decreasing tumor growth, and increasing survival in our model. Furthermore, tumor-infiltrating T cells demonstrated a pattern of checkpoint expression similar to other checkpoint blockade-susceptible tumors. CONCLUSIONS This suggests that immunotherapy, particularly blockade of the PD1/PD-L1 axis, may be a novel therapeutic option for refractory Cushing disease. Clinical investigation is encouraged.
Collapse
Affiliation(s)
- Hanna R Kemeny
- Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.,Duke University School of Medicine, Durham, North Carolina
| | - Aladine A Elsamadicy
- Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.,Duke University School of Medicine, Durham, North Carolina
| | - S Harrison Farber
- Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.,Duke University School of Medicine, Durham, North Carolina
| | - Cosette D Champion
- Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.,Duke University School of Medicine, Durham, North Carolina
| | - Selena J Lorrey
- Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina
| | - Pakawat Chongsathidkiet
- Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.,Department of Pathology, Duke University Medical Center, Durham, North Carolina
| | - Karolina I Woroniecka
- Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.,Department of Pathology, Duke University Medical Center, Durham, North Carolina
| | - Xiuyu Cui
- Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina
| | - Steven H Shen
- Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.,Duke University School of Medicine, Durham, North Carolina
| | - Kristen E Rhodin
- Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.,Duke University School of Medicine, Durham, North Carolina
| | - Vadim Tsvankin
- Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina
| | - Jeffrey Everitt
- Department of Pathology, Duke University Medical Center, Durham, North Carolina
| | - Luis Sanchez-Perez
- Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina
| | - Patrick Healy
- Department of Biostatistics, Duke University, Durham, North Carolina
| | - Roger E McLendon
- Department of Pathology, Duke University Medical Center, Durham, North Carolina
| | - Patrick J Codd
- Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina
| | - Ian F Dunn
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Peter E Fecci
- Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina. .,Duke University School of Medicine, Durham, North Carolina.,Department of Pathology, Duke University Medical Center, Durham, North Carolina
| |
Collapse
|
14
|
Sbiera S, Kunz M, Weigand I, Deutschbein T, Dandekar T, Fassnacht M. The New Genetic Landscape of Cushing's Disease: Deubiquitinases in the Spotlight. Cancers (Basel) 2019; 11:cancers11111761. [PMID: 31717455 PMCID: PMC6895825 DOI: 10.3390/cancers11111761] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2019] [Revised: 10/28/2019] [Accepted: 11/04/2019] [Indexed: 12/20/2022] Open
Abstract
Cushing’s disease (CD) is a rare condition caused by adrenocorticotropic hormone (ACTH)-producing adenomas of the pituitary, which lead to hypercortisolism that is associated with high morbidity and mortality. Treatment options in case of persistent or recurrent disease are limited, but new insights into the pathogenesis of CD are raising hope for new therapeutic avenues. Here, we have performed a meta-analysis of the available sequencing data in CD to create a comprehensive picture of CD’s genetics. Our analyses clearly indicate that somatic mutations in the deubiquitinases are the key drivers in CD, namely USP8 (36.5%) and USP48 (13.3%). While in USP48 only Met415 is affected by mutations, in USP8 there are 26 different mutations described. However, these different mutations are clustering in the same hotspot region (affecting in 94.5% of cases Ser718 and Pro720). In contrast, pathogenic variants classically associated with tumorigenesis in genes like TP53 and BRAF are also present in CD but with low incidence (12.5% and 7%). Importantly, several of these mutations might have therapeutic potential as there are drugs already investigated in preclinical and clinical setting for other diseases. Furthermore, network and pathway analyses of all somatic mutations in CD suggest a rather unified picture hinting towards converging oncogenic pathways.
Collapse
Affiliation(s)
- Silviu Sbiera
- Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, D-97080 Würzburg, Germany; (I.W.); (T.D.); (M.F.)
- Comprehensive Cancer Center Mainfranken, University of Würzburg, D-97080 Würzburg, Germany
- Correspondence:
| | - Meik Kunz
- Chair of Medical Informatics, Friedrich-Alexander University of Erlangen-Nürnberg, D-91058 Erlangen, Germany;
| | - Isabel Weigand
- Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, D-97080 Würzburg, Germany; (I.W.); (T.D.); (M.F.)
| | - Timo Deutschbein
- Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, D-97080 Würzburg, Germany; (I.W.); (T.D.); (M.F.)
| | - Thomas Dandekar
- Department of Bioinformatics, Biocenter, University of Würzburg, D-97074 Würzburg, Germany;
| | - Martin Fassnacht
- Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, D-97080 Würzburg, Germany; (I.W.); (T.D.); (M.F.)
- Comprehensive Cancer Center Mainfranken, University of Würzburg, D-97080 Würzburg, Germany
| |
Collapse
|
15
|
Wanichi IQ, de Paula Mariani BM, Frassetto FP, Siqueira SAC, de Castro Musolino NR, Cunha-Neto MBC, Ochman G, Cescato VAS, Machado MC, Trarbach EB, Bronstein MD, Fragoso MCBV. Cushing's disease due to somatic USP8 mutations: a systematic review and meta-analysis. Pituitary 2019; 22:435-442. [PMID: 31273566 DOI: 10.1007/s11102-019-00973-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
PURPOSE Cushing's disease (CD) is a severe illness generally caused by microcorticotropinomas (MICs) and in approximately 7-20% of patients by macrocorticotropinomas (MACs). USP8-mutations have been identified as a major genetic cause of CD (~ 50%). Few studies have reported the distribution between MICs-MACs related to USP8-mutations and their genotype-phenotype correlations. Therefore, we aimed to evaluate USP8-mutations in a cohort of MICs-MACs from a unique center and to perform a systematic review and meta-analysis. METHODS DNA-tumor-tissues from 47 corticotropinomas (16 MICs and 31 MACs) were sequenced. Clinical-biochemical data, radiological imaging data and remission/recurrence rates were evaluated. In addition, we performed a meta-analysis of nine published series (n = 630). RESULTS We identified four different USP8-mutations previously described, in 11 out of 47 (23.4%) corticotropinomas; 8 out of 11 were MACs. The urinary cortisol levels of our patients with corticotrophin USP8-mutated-alleles were lower than those of patients with wild-type (WT) alleles (p ≤ 0.017). The frequency of USP8-mutated-alleles among the series was approximately 30% with a higher prevalence in female-patients (p < 0.1 × 10-4). Among the 5 series, the remission rates were higher in patients with USP8-mutated-alleles than in those with the USP8-WT-alleles (p < 0.1 × 10-4). CONCLUSION Our data, as well as the retrospective review of CD series associated with USP8-mutated alleles, show heterogeneous findings among the series. Several drawbacks included the lack of a systematic protocol to evaluate these patients before surgery and follow-up. Further prospective studies using a systematic protocol will provide more consistent information about the influence of the corticotropinomas with USP8-mutated alleles on the phenotype, responses to treatment and outcome of patients with CD.
Collapse
Affiliation(s)
- Ingrid Quevedo Wanichi
- Laboratório de Hormônios e Genética Molecular (LIM/42) do Hospital das Clinicas da Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da, Universidade de São Paulo, Avenida Dr.Enéas de Carvalho Aguiar, 155 - 2 andar bloco 6, São Paulo, CEP 05403900, Brazil
| | - Beatriz Marinho de Paula Mariani
- Laboratório de Hormônios e Genética Molecular (LIM/42) do Hospital das Clinicas da Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da, Universidade de São Paulo, Avenida Dr.Enéas de Carvalho Aguiar, 155 - 2 andar bloco 6, São Paulo, CEP 05403900, Brazil
| | - Fernando Pereira Frassetto
- Departamento de Patologia do Hospital das Clinicas da Faculdade de Medicina da, Universidade de São Paulo, São Paulo, Brazil
| | | | - Nina Rosa de Castro Musolino
- Unidade de Neuroendocrinologia da Divisão de Neurocirurgia Funcional, Instituto de Psiquiatria do Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | - Malebranche Berardo Carneiro Cunha-Neto
- Unidade de Neuroendocrinologia da Divisão de Neurocirurgia Funcional, Instituto de Psiquiatria do Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | - Gilberto Ochman
- Unidade de Neuroendocrinologia da Divisão de Neurocirurgia Funcional, Instituto de Psiquiatria do Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | - Valter Angelo Sperling Cescato
- Unidade de Neuroendocrinologia da Divisão de Neurocirurgia Funcional, Instituto de Psiquiatria do Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | - Marcio Carlos Machado
- Unidade de Neuroendocrinologia da Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da, Universidade de São Paulo, São Paulo, Brazil
- Endocrinology Service, AC Camargo Cancer Center, São Paulo, Brazil
- Laboratorio de Endocrinologia Celular e Molecular (LIM/25) do Hospital das Clinicas da Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da, Universidade de São Paulo, São Paulo, Brazil
| | - Ericka Barbosa Trarbach
- Laboratorio de Endocrinologia Celular e Molecular (LIM/25) do Hospital das Clinicas da Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da, Universidade de São Paulo, São Paulo, Brazil
| | - Marcello Delano Bronstein
- Unidade de Neuroendocrinologia da Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da, Universidade de São Paulo, São Paulo, Brazil
- Laboratorio de Endocrinologia Celular e Molecular (LIM/25) do Hospital das Clinicas da Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da, Universidade de São Paulo, São Paulo, Brazil
| | - Maria Candida Barisson Villares Fragoso
- Laboratório de Hormônios e Genética Molecular (LIM/42) do Hospital das Clinicas da Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da, Universidade de São Paulo, Avenida Dr.Enéas de Carvalho Aguiar, 155 - 2 andar bloco 6, São Paulo, CEP 05403900, Brazil.
- Unidade de Suprarrenal da Disciplina de Endocrinologia e Metabologia da Faculdade de Medicina da, Universidade de São Paulo, São Paulo, Brazil.
- Clinica de Bases do Instituto do Câncer do Estado de São Paulo, ICESP, São Paulo, Brazil.
| |
Collapse
|
16
|
Weigand I, Knobloch L, Flitsch J, Saeger W, Monoranu CM, Höfner K, Herterich S, Rotermund R, Ronchi CL, Buchfelder M, Glatzel M, Hagel C, Fassnacht M, Deutschbein T, Sbiera S. Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease. J Clin Endocrinol Metab 2019; 104:2535-2546. [PMID: 30844069 DOI: 10.1210/jc.2018-02564] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/28/2018] [Accepted: 03/01/2019] [Indexed: 02/01/2023]
Abstract
CONTEXT Cushing disease (CD) is a rare disorder with severe sequels and incompletely understood pathogenesis. The underlying corticotroph adenomas harbor frequently somatic mutations in the ubiquitin-specific peptidase 8 (USP8) gene. These mutations render USP8 hyperactive and prevent client proteins from degradation. OBJECTIVE To investigate the impact of USP8 mutations on proteins deregulated in CD. DESIGN One hundred eight pituitary adenomas (75 corticotroph [58 USP8 wild type (WT) and 17 USP8 mutated], 14 somatotroph, and 19 nonfunctioning) were investigated by immunohistochemistry. All evaluated proteins [USP8, arginine vasopressin receptor 1b and 2, corticotropin-releasing hormone receptor, cAMP response element-binding protein (CREB), p27/kip1, cyclin E, heat shock protein 90 (HSP90), orphan nuclear receptor 4, epidermal growth factor receptor, histone deacetylase 2, glucocorticoid receptor, cyclin-dependent kinase 5 and Abelson murine leukemia viral oncogene homolog 1 enzyme substrate 1] were known to be deregulated in CD. Furthermore, AtT20 cells were transfected with USP8 to investigate the expression of possible downstream proteins by immunoblot. RESULTS Whereas most of the investigated proteins were not differentially expressed, the cell-cycle inhibitor p27 was significantly reduced in USP8 mutated corticotroph adenoma (H-score 2.0 ± 1.0 vs 1.1 ± 1.1 in WT adenomas; P = 0.004). In contrast, the chaperone HSP90 was expressed higher (0.5 ± 0.4 vs 0.2 ± 0.4; P = 0.29), and the phosphorylation of the transcription factor CREB was increased in USP8 mutated adenomas (1.30.5 ± 0.40.9 vs 0.70.5 ± 0.40.7; P = 0.014). Accordingly, AtT20 cells transfected with the USP8 P720R mutant had higher phosphorylated CREB (pCREB) levels than WT transfected cells (1.3 ± 0.14 vs 1 ± 0.23; P = 0.13). CONCLUSIONS We could demonstrate that USP8 mutations are associated with deregulation of p27/kip1, HSP90, and pCREB. These findings suggest that these proteins are direct or indirect clients of USP8 and could therefore be potential targets for therapeutic approaches in patients with CD.
Collapse
Affiliation(s)
- Isabel Weigand
- Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, Wuerzburg, Germany
| | - Lisanne Knobloch
- Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, Wuerzburg, Germany
| | - Jörg Flitsch
- Department of Neurosurgery, University Hospital of Hamburg-Eppendorf, Hamburg, Germany
| | - Wolfgang Saeger
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Camelia M Monoranu
- Department of Neuropathology, Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany
| | - Kerstin Höfner
- Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, Wuerzburg, Germany
| | - Sabine Herterich
- Central Laboratory, University Hospital Wuerzburg, Wuerzburg, Germany
| | - Roman Rotermund
- Department of Neurosurgery, University Hospital of Hamburg-Eppendorf, Hamburg, Germany
| | - Cristina L Ronchi
- Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, Wuerzburg, Germany
- Institute of Metabolism and System Research, University of Birmingham, Birmingham, United Kingdom
| | - Michael Buchfelder
- Department of Neurosurgery, University of Erlangen-Nuernberg, Erlangen, Germany
| | - Markus Glatzel
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Christian Hagel
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Martin Fassnacht
- Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, Wuerzburg, Germany
- Central Laboratory, University Hospital Wuerzburg, Wuerzburg, Germany
- Comprehensive Cancer Center Mainfranken, University of Wuerzburg, Wuerzburg, Germany
| | - Timo Deutschbein
- Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, Wuerzburg, Germany
| | - Silviu Sbiera
- Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, Wuerzburg, Germany
| |
Collapse
|
17
|
Ren J, Gu C, Yang Y, Xue J, Sun Y, Jian F, Chen D, Bian L, Sun Q. TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease. J Cell Mol Med 2019; 23:4097-4110. [PMID: 31016850 PMCID: PMC6533510 DOI: 10.1111/jcmm.14297] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Revised: 01/29/2019] [Accepted: 03/04/2019] [Indexed: 12/11/2022] Open
Abstract
The pathogenesis of Cushing's disease, which is caused by pituitary corticotroph adenoma, remains to be studied. Secreted angioinhibitory factor thrombospondin-1 (TSP-1) is an adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions and is associated with platelet aggregation, angiogenesis and tumorigenesis. We have found that the expression of TSP-1 is significantly lower in human pituitary corticotroph tumours compared with normal adenohypophysis. This study aims to elucidate the role of TSP-1 in regulating the tumour function of pituitary adenomas. Forced overexpression of TSP-1 in a murine AtT20 pituitary corticotroph tumour cell line decreased corticotroph precursor hormone proopiomelanocortin (POMC) transcription and adrenocorticotropic hormone (ACTH) secretion. Functional studies showed that TSP-1 overexpression in pituitary adenoma cells suppressed proliferation, migration and invasion. We have demonstrated that TSP-1 is a direct target of miR-449c. Further study showed that miR-449c activity enhanced tumorigenesis by directly inhibiting TSP-1 expression. Low expression of lncTHBS1, along with low expression of TSP-1, was associated with the high expression of miR-449c in Cushing's disease patients. Furthermore, RNA-immunoprecipitation associates miR-449c with lncTHBS1 suggesting that lncTHBS1 might be a negative regulator of miR-449c. Taken together, this study has demonstrated that lncTHBS1 might function as competing endogenous RNA for miR-449c, which could suppress the development of Cushing's disease.
Collapse
Affiliation(s)
- Jie Ren
- Department of Neurosurgery, Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiP.R. China
| | - Changwei Gu
- Department of Neurosurgery, Ruijin Hospital, Luwan BranchShanghai Jiaotong University School of MedicineShanghaiP.R. China
| | - Yong Yang
- Department of NeurosurgeryGuangdong General Hospital, Guangdong Academy of Medical SciencesGuangzhouChina
| | - Jun Xue
- Department of Neurosurgery, Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiP.R. China
| | - Yuhao Sun
- Department of Neurosurgery, Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiP.R. China
| | - Fangfang Jian
- Department of Obstetrics and Gynecology, Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiP.R. China
| | - Dongjiang Chen
- Department of Neurosurgery, McKnight Brain InstituteUniversity of FloridaGainesvilleFlorida
| | - Liuguan Bian
- Department of Neurosurgery, Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiP.R. China
| | - Qingfang Sun
- Department of Neurosurgery, Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiP.R. China
- Department of Neurosurgery, Ruijin Hospital, Luwan BranchShanghai Jiaotong University School of MedicineShanghaiP.R. China
| |
Collapse
|
18
|
Herrera-Martínez AD, Feelders RA, de Herder WW, Castaño JP, Gálvez Moreno MÁ, Dogan F, van Dungen R, van Koetsveld P, Hofland LJ. Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells. HORMONES & CANCER 2019; 10:107-119. [PMID: 31102172 DOI: 10.1007/s12672-019-00361-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/27/2018] [Accepted: 03/28/2019] [Indexed: 02/08/2023]
Abstract
Prolonged remission of hypercortisolism with steroidogenesis inhibitors has been described in patients with ectopic adrenocorticotropic hormone (ACTH) syndrome. The anti-proliferative and pro-apoptotic effect of ketoconazole in human cancer cells was previously suggested. The aim of this study was to explore the effects of ketoconazole on ACTH-producing and non-ACTH-producing neuroendocrine tumor (NET) cell lines. The effects of ketoconazole alone, and in combination with somatostatin analogs, were evaluated in two human cell lines: DMS-79 (ectopic ACTH-producing small cell lung carcinoma) and BON-1 (human pancreatic NET). Total DNA measurement, apoptosis, cell cycle, chromogranin A (CgA)/proopiomelanocortin (POMC) expression by qRT-PCR, serotonin, CgA, and ACTH secretion assays were performed. In both cell lines, ketoconazole significantly suppressed cell growth and colony formation in a dose and time-dependent manner. The effect in DMS-79 was primarily cytotoxic, while it was more apoptotic in BON-1 cells. Ketoconazole also induced increase in G0/G1 phase in both cell lines and arrest in phase G2/M of BON-1 cells. Ketoconazole did not affect the secretion of serotonin, CgA, ACTH, or the mRNA expression of CgA and POMC. Decreased serotonin secretion was observed after the combination treatment with pasireotide. These results suggest a direct effect of ketoconazole on cell proliferation, apoptosis, and cell cycle in both ACTH- and non-ACTH-producing NET cells.
Collapse
Affiliation(s)
- Aura D Herrera-Martínez
- Department of Internal Medicine, Division of Endocrinology, Erasmus MC, Wytemaweg 80, 3015, CN, Rotterdam, The Netherlands.,Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain
| | - Richard A Feelders
- Department of Internal Medicine, Division of Endocrinology, Erasmus MC, Wytemaweg 80, 3015, CN, Rotterdam, The Netherlands
| | - Wouter W de Herder
- Department of Internal Medicine, Division of Endocrinology, Erasmus MC, Wytemaweg 80, 3015, CN, Rotterdam, The Netherlands
| | - Justo P Castaño
- Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain
| | | | - Fadime Dogan
- Department of Internal Medicine, Division of Endocrinology, Erasmus MC, Wytemaweg 80, 3015, CN, Rotterdam, The Netherlands
| | - Rosanna van Dungen
- Department of Internal Medicine, Division of Endocrinology, Erasmus MC, Wytemaweg 80, 3015, CN, Rotterdam, The Netherlands
| | - Peter van Koetsveld
- Department of Internal Medicine, Division of Endocrinology, Erasmus MC, Wytemaweg 80, 3015, CN, Rotterdam, The Netherlands
| | - Leo J Hofland
- Department of Internal Medicine, Division of Endocrinology, Erasmus MC, Wytemaweg 80, 3015, CN, Rotterdam, The Netherlands.
| |
Collapse
|
19
|
Feelders RA, Newell-Price J, Pivonello R, Nieman LK, Hofland LJ, Lacroix A. Advances in the medical treatment of Cushing's syndrome. Lancet Diabetes Endocrinol 2019; 7:300-312. [PMID: 30033041 DOI: 10.1016/s2213-8587(18)30155-4] [Citation(s) in RCA: 70] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2018] [Revised: 04/30/2018] [Accepted: 05/08/2018] [Indexed: 01/05/2023]
Abstract
Cushing's syndrome is associated with multisystem morbidity and, when suboptimally treated, increased mortality. Medical therapy is an option for patients if surgery is not successful and can be classified into pituitary-directed drugs, steroid synthesis inhibitors, and glucocorticoid receptor antagonists. In the last decade there have been new developments in each drug category. Targeting dopamine and somatostatin receptors on corticotroph adenomas with cabergoline or pasireotide, or both, controls cortisol production in up to 40% of patients. Potential new targets in corticotroph adenomas include the epidermal growth factor receptor, cyclin-dependent kinases, and heat shock protein 90. Osilodrostat and levoketoconazole are new inhibitors of steroidogenesis and are currently being evaluated in multicentre trials. CORT125134 is a new selective glucocorticoid receptor antagonist under investigation. We summarise the drug therapies for various forms of Cushing's syndrome and focus on emerging drugs and drug targets that have the potential for new and effective tailor-made pharmacotherapy for patients with Cushing's syndrome.
Collapse
Affiliation(s)
- Richard A Feelders
- Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Centre, Rotterdam, Netherlands.
| | - John Newell-Price
- Academic Unit of Endocrinology, University of Sheffield, Sheffield, UK
| | - Rosario Pivonello
- Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy
| | - Lynnette K Nieman
- Eunice Kennedy Shriver National Institute of Diabetes and Kidney Disease, National Institutes of Health, Bethesda, MD, USA
| | - Leo J Hofland
- Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Centre, Rotterdam, Netherlands
| | - Andre Lacroix
- Division of Endocrinology, Department of Medicine and Research Centre, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada
| |
Collapse
|
20
|
Nagendra L, Bhavani N, Pavithran PV, Kumar GP, Menon UV, Menon AS, Kumar L, Kumar H, Nair V, Abraham N, Narayanan P. Outcomes of Bilateral Adrenalectomy in Cushing's Syndrome. Indian J Endocrinol Metab 2019; 23:193-197. [PMID: 31161102 PMCID: PMC6540899 DOI: 10.4103/ijem.ijem_654_18] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
CONTEXT The literature on outcomes of bilateral adrenalectomy (BADx) in Cushing's syndrome (CS) is scant. AIMS The aim of this study is to analyze the short- and long-term outcomes of patients who underwent BADx and to compare the outcomes among different etiologies of CS. SETTINGS AND DESIGN This is a retrospective analysis of patients who underwent BADx for CS at our center between 2005 and 2018. MATERIALS AND METHODS In all, 33 patients were studied for clinical outcomes, survival rates, and long-term complications. STATISTICAL ANALYSIS All analyses were performed with SPSS software (version 21.0). RESULTS The mean age at surgery was 39.33 ± 15.67 years. The primary etiology for CS was Cushing's disease (CD) in 42.42%, ectopic source in 36.36%, primary pigmented nodular adrenocortical disease (PPNAD) in 12.12%, and adrenocorticotrophin hormone-independent macronodular adrenal hyperplasia (AIMAH) in 9.09% of patients. The median follow-up time was 72.77 months. Improvement in hypertension and diabetes status after surgery was seen in 78% and 76.19% of patients, respectively. Proximal myopathy improved in 68% of patients. Nelson's syndrome and adrenal crisis were seen in 21.4% of patients each on long-term follow-up. Total mortality after BADx was 33.3%. Mortality in the first 30 days after surgery was seen in five patients (15.15%). Higher cortisol levels at presentation and age more than 40 years were predictors of mortality. Among the Cushing's subtypes, PPNAD had the best prognosis followed by CD. Perioperative Infections were a major cause of mortality. CONCLUSION BADx is an effective treatment for CS especially in patients with PPNAD and CD but carries a significant mortality rate too.
Collapse
Affiliation(s)
- Lakshmi Nagendra
- Department of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Cochin, Kerala, India
| | - Nisha Bhavani
- Department of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Cochin, Kerala, India
| | - Praveen V. Pavithran
- Department of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Cochin, Kerala, India
| | - Ginil P. Kumar
- Department of Urology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Cochin, Kerala, India
| | - Usha V. Menon
- Department of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Cochin, Kerala, India
| | - Arun S. Menon
- Department of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Cochin, Kerala, India
| | - Lakshmi Kumar
- Department of Anaesthesiology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Cochin, Kerala, India
| | - Harish Kumar
- Department of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Cochin, Kerala, India
| | - Vasantha Nair
- Department of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Cochin, Kerala, India
| | - Nithya Abraham
- Department of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Cochin, Kerala, India
| | - Prem Narayanan
- Department of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Cochin, Kerala, India
| |
Collapse
|
21
|
Gatto F, Arvigo M, Amarù J, Campana C, Cocchiara F, Graziani G, Bruzzone E, Giusti M, Boschetti M, Ferone D. Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells. Pituitary 2019; 22:89-99. [PMID: 30483918 DOI: 10.1007/s11102-018-0926-y] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND Pasireotide is a second-generation somatostatin (SRIF) receptor ligand (SRL), approved for medical treatment of acromegaly and Cushing's disease (CD). The molecule is a stable cyclohexapeptide synthetized based on SRIF structure. Differently from first-generation SRLs (e.g. octreotide), preferentially binding somatostatin receptor (SST) subtype 2 (SST2), pasireotide has high affinity for multiple SSTs (SST5 > SST2 > SST3 > SST1). Interestingly, early preclinical studies demonstrated that pasireotide shows distinct functional properties compared to SRIF and first-generation SRLs when binding SSTs. METHODS We aimed to highlight the differential receptor-targeted action of pasireotide in the treatment of somatotroph and corticotroph adenomas, throughout the critical revision of preclinical studies carried out on acromegaly and CD models. RESULTS Different authors demonstrated that the antisecretory effect of pasireotide in somatotroph adenoma cell cultures is comparable to that of the SST2-preferential agonist octreotide. Some reports even show a direct correlation between SST2 mRNA expression and GH reduction after pasireotide treatment, thus laying for a predominant role of SST2 in driving pasireotide efficacy in somatotropinomas in vitro. On the other hand, the inhibitory effect of pasireotide on ACTH secretion in corticotropinoma cells seems to be mainly mediated by SST5. Indeed, most reports show a higher potency and efficacy of pasireotide compared to SST2 preferential agonists, while functional studies confirm the pivotal role of SST5 targeting in corticotroph cells. CONCLUSIONS The analysis of preclinical studies carried out in somatotroph and corticoph adenomas points out that pasireotide shows a cell-specific activity, exerting its biological effects via different SSTs in the different adenoma histotypes.
Collapse
Affiliation(s)
- Federico Gatto
- Endocrinology Unit, Department of Internal Medicine, Policlinico San Martino, 16132, Genoa, Italy.
| | | | | | | | | | | | | | - Massimo Giusti
- Endocrinology Unit, Department of Internal Medicine, Policlinico San Martino, 16132, Genoa, Italy
- University of Genoa, Genoa, Italy
| | - Mara Boschetti
- Endocrinology Unit, Department of Internal Medicine, Policlinico San Martino, 16132, Genoa, Italy
- University of Genoa, Genoa, Italy
| | - Diego Ferone
- Endocrinology Unit, Department of Internal Medicine, Policlinico San Martino, 16132, Genoa, Italy
- University of Genoa, Genoa, Italy
| |
Collapse
|
22
|
Abstract
INTRODUCTION Cushing's disease is a rare systemic and disabling disease due to oversecretion of adrenocorticotrophic hormone (ACTH) resulting in excess cortisol levels. Diagnosis and treatment are difficult; despite the availability of various pharmaceutical treatment options, there is an ongoing, unmet need for even more effective treatment. AREAS COVERED The present review aims at providing an overview of available drugs and presenting new developments. Focusing on the pituitary as a target, the review covers compounds targeting pituitary cell signaling or cell cycle control such as heat shock protein inhibitors (e.g. silibinin), histone deacetylase inhibitors (trichostatin A, vorinostat), kinase inhibitors (gefitinib, seliciclib), and others (such as triptolide, AT-101). Levoketoconazole and osilodrostat are in clinical testing and inhibit steroidogenesis. Blockade of ACTH receptor binding at the adrenal level is explained as a theoretical drug target. Inhibition of binding of the glucocorticoid receptor in the peripheral tissue plays a minor role due to its lack of biomonitoring options. EXPERT OPINION In our opinion, further research and drug development of pituitary-directed targets are necessary. Combination therapies may exert synergistic effects and allow for smaller and better tolerated doses, but more experience and data are needed to guide such treatment schemes.
Collapse
Affiliation(s)
- Sylvère Störmann
- a Medizinische Klinik und Poliklinik IV , Klinikum der Universität München , München , Germany
| | - Jochen Schopohl
- a Medizinische Klinik und Poliklinik IV , Klinikum der Universität München , München , Germany
| |
Collapse
|
23
|
Frau R, Bortolato M. Repurposing steroidogenesis inhibitors for the therapy of neuropsychiatric disorders: Promises and caveats. Neuropharmacology 2018; 147:55-65. [PMID: 29907425 DOI: 10.1016/j.neuropharm.2018.05.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2018] [Revised: 05/07/2018] [Accepted: 05/10/2018] [Indexed: 12/29/2022]
Abstract
Steroids exert a profound influence on behavioral reactivity, by modulating the functions of most neurotransmitters and shaping the impact of stress and sex-related variables on neural processes. This background - as well as the observation that most neuroactive steroids (including sex hormones, glucocorticoids and neurosteroids) are synthetized and metabolized by overlapping enzymatic machineries - points to steroidogenic pathways as a powerful source of targets for neuropsychiatric disorders. Inhibitors of steroidogenic enzymes have been developed and approved for a broad range of genitourinary and endocrine dysfunctions, opening to new opportunities to repurpose these drugs for the treatment of mental problems. In line with this idea, preliminary clinical and preclinical results from our group have shown that inhibitors of key steroidogenic enzymes, such as 5α-reductase and 17,20 desmolase-lyase, may have therapeutic efficacy in specific behavioral disorders associated with dopaminergic hyperfunction. While the lack of specificity of these effects raises potential concerns about endocrine adverse events, these initial findings suggest that steroidogenesis modulators with greater brain specificity may hold significant potential for the development of alternative therapies for psychiatric problems. This article is part of the Special Issue entitled 'Drug Repurposing: old molecules, new ways to fast track drug discovery and development for CNS disorders'.
Collapse
Affiliation(s)
- Roberto Frau
- Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, Monserrato CA, Italy; Tourette Syndrome Center, University of Cagliari, Monserrato CA, Italy; Sleep Medicine Center, University of Cagliari, Monserrato CA, Italy; National Institute of Neuroscience (INN), University of Cagliari, Monserrato CA, Italy.
| | - Marco Bortolato
- Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.
| |
Collapse
|
24
|
Zaidi HA, Penn DL, Cote DJ, Laws ER. Root cause analysis of diagnostic and surgical failures in the treatment of suspected Cushing's disease. J Clin Neurosci 2018; 53:153-159. [PMID: 29716804 DOI: 10.1016/j.jocn.2018.04.055] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Accepted: 04/23/2018] [Indexed: 11/15/2022]
Abstract
Cushing's disease (CD) is a condition characterized by excess glucocorticoid from an ACTH pituitary adenoma. Identifying surgical candidates represents a major diagnostic challenge. We performed a root cause analysis (RCA) of treatment failures for patients with suspected CD. The present study aims to categorize failures in treatment. Medical records were reviewed from 2008 to 2017 for all patients treated surgically for suspected CD. Demographics, past medical history, endocrine outcomes, imaging findings, laboratory studies and clinical features were collected. Eighty-five patients were identified with pre-operative suspicion for CD. Thirty-four (40.0%) had undergone prior surgery confirming ACTH adenoma, leaving 51 (60.0%) for analysis. The average length of follow-up was 18.3 ± 24.1 months, 42 (82.4%) patients had postoperative biochemical remission of hypercortisolism. Forty-three (84.3%) had histologically confirmed CD, two (3.9%) were diagnosed with extracranial ACTH-secreting tumors, four (7.8%) had no obvious tumor upon intraoperative exploration, one (1.9%) had suspected pituitary ACTH hyperplasia, and one (1.9%) had no identifiable pathologic tissue despite apparent gross tumor observed during surgery. Thirty-four (66.7%) patients had remission following surgery alone, four (7.8%) after reoperation, and four (7.81%) after radiosurgery. One patient (1.9%) was found to have an ectopic source of ACTH, and one (1.9%) had immunohistochemically confirmed adrenal tumors. On RCA, we identified six categories of treatment failures. CD is a diagnostic challenge that can be difficult to distinguish from other forms of hypercortisolism. Surgical efficacy can be improved with more accurate patient selection, and perhaps with improved imaging methods.
Collapse
Affiliation(s)
- Hasan A Zaidi
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - David L Penn
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - David J Cote
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Edward R Laws
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
| |
Collapse
|
25
|
Bertagna X. MANAGEMENT OF ENDOCRINE DISEASE: Can we cure Cushing's disease? A personal view. Eur J Endocrinol 2018; 178:R183-R200. [PMID: 29467229 DOI: 10.1530/eje-18-0062] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Accepted: 02/20/2018] [Indexed: 12/21/2022]
Abstract
One of today's challenges in endocrinology is the treatment of Cushing's disease: Although pituitary surgery has the potential to 'cure' the patient and restore a completely normal pituitary adrenal axis, there are immediate failures and late recurrences that will ultimately require alternate therapeutic approaches. Their high number is in direct correlation with their serious limitations and they all appear to be 'default options'. This 'personal view' tries to shed some light on the inescapable difficulties of the current treatments of Cushing's disease and to provide some optimistic view for the future where the pituitary adenoma should be the 'reasonable obsession' of a successful therapeutist.
Collapse
Affiliation(s)
- X Bertagna
- Service des Maladies Endocriniennes et MétaboliquesCentre de Référence des Maladies Rares de la Surrénale, Hôpital Cochin, Faculté de Médecine Paris Descartes, Université Paris 5, Paris, France
| |
Collapse
|
26
|
Machado MC, Fragoso MCBV, Moreira AC, Boguszewski CL, Vieira Neto L, Naves LA, Vilar L, Araújo LAD, Musolino NRC, Miranda PAC, Czepielewski MA, Gadelha MR, Bronstein MD, Ribeiro-Oliveira A. A review of Cushing's disease treatment by the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism. ARCHIVES OF ENDOCRINOLOGY AND METABOLISM 2018; 62:87-105. [PMID: 29694638 PMCID: PMC10118687 DOI: 10.20945/2359-3997000000014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Accepted: 10/02/2017] [Indexed: 11/23/2022]
Abstract
The treatment objectives for a patient with Cushing's disease (CD) are remission of hypercortisolism, adequate management of co-morbidities, restoration of the hypothalamic-pituitary-adrenal axis, preservation of fertility and pituitary function, and improvement of visual defects in cases of macroadenomas with suprasellar extension. Transsphenoidal pituitary surgery is the main treatment option for the majority of cases, even in macroadenomas with low probability of remission. In cases of surgical failure, another subsequent pituitary surgery might be indicated in cases with persistent tumor imaging at post surgical magnetic resonance imaging (MRI) and/or pathology analysis of adrenocorticotropic hormone-positive (ACTH+) positive pituitary adenoma in the first procedure. Medical treatment, radiotherapy and adrenalectomy are the other options when transsphenoidal pituitary surgery fails. There are several options of medical treatment, although cabergoline and ketoconazole are the most commonly used alone or in combination. Novel treatments are also addressed in this review. Different therapeutic approaches are frequently needed on an individual basis, both before and, particularly, after surgery, and they should be individualized. The objective of the present review is to provide the necessary information to achieve a more effective treatment for CD. It is recommended that patients with CD be followed at tertiary care centers with experience in treating this condition.
Collapse
Affiliation(s)
- Márcio Carlos Machado
- Unidade de Neuroendocrinologia, Serviço de Endocrinologia e Metabologia, Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| | - Maria Candida Barisson Vilares Fragoso
- Unidade de Neuroendocrinologia, Serviço de Endocrinologia e Metabologia, Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| | - Ayrton Custódio Moreira
- Divisão de Endocrinologia e Metabologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
| | - César Luiz Boguszewski
- Serviço de Endocrinologia e Metabologia (SEMPR), Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, PR, Brasil
| | - Leonardo Vieira Neto
- Serviço de Endocrinologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil
| | - Luciana A Naves
- Serviço de Endocrinologia, Hospital Universitário de Brasília, Universidade de Brasília, Brasília, DF, Brasil
| | - Lucio Vilar
- Serviço de Endocrinologia, Hospital de Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brasil
| | | | - Nina Rosa Castro Musolino
- Divisão de Neurocirurgia Funcional, Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| | | | - Mauro A Czepielewski
- Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil
| | - Monica R Gadelha
- Serviço de Endocrinologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil
| | - Marcello Delano Bronstein
- Unidade de Neuroendocrinologia, Serviço de Endocrinologia e Metabologia, Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| | - Antônio Ribeiro-Oliveira
- Serviço de Endocrinologia, Hospital de Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil
| |
Collapse
|
27
|
Valassi E, Franz H, Brue T, Feelders RA, Netea-Maier R, Tsagarakis S, Webb SM, Yaneva M, Reincke M, Droste M, Komerdus I, Maiter D, Kastelan D, Chanson P, Pfeifer M, Strasburger CJ, Tóth M, Chabre O, Krsek M, Fajardo C, Bolanowski M, Santos A, Trainer PJ, Wass JAH, Tabarin A. Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. Eur J Endocrinol 2018; 178:399-409. [PMID: 29440375 DOI: 10.1530/eje-17-0997] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2017] [Accepted: 02/12/2018] [Indexed: 01/03/2023]
Abstract
BACKGROUND Surgery is the definitive treatment of Cushing's syndrome (CS) but medications may also be used as a first-line therapy. Whether preoperative medical treatment (PMT) affects postoperative outcome remains controversial. OBJECTIVE (1) Evaluate how frequently PMT is given to CS patients across Europe; (2) examine differences in preoperative characteristics of patients who receive PMT and those who undergo primary surgery and (3) determine if PMT influences postoperative outcome in pituitary-dependent CS (PIT-CS). PATIENTS AND METHODS 1143 CS patients entered into the ERCUSYN database from 57 centers in 26 countries. Sixty-nine percent had PIT-CS, 25% adrenal-dependent CS (ADR-CS), 5% CS from an ectopic source (ECT-CS) and 1% were classified as having CS from other causes (OTH-CS). RESULTS Twenty per cent of patients took PMT. ECT-CS and PIT-CS were more likely to receive PMT compared to ADR-CS (P < 0.001). Most commonly used drugs were ketoconazole (62%), metyrapone (16%) and a combination of both (12%). Median (interquartile range) duration of PMT was 109 (98) days. PIT-CS patients treated with PMT had more severe clinical features at diagnosis and poorer quality of life compared to those undergoing primary surgery (SX) (P < 0.05). Within 7 days of surgery, PIT-CS patients treated with PMT were more likely to have normal cortisol (P < 0.01) and a lower remission rate (P < 0.01). Within 6 months of surgery, no differences in morbidity or remission rates were observed between SX and PMT groups. CONCLUSIONS PMT may confound the interpretation of immediate postoperative outcome. Follow-up is recommended to definitely evaluate surgical results.
Collapse
Affiliation(s)
- Elena Valassi
- IIB-Sant Pau and Department of Endocrinology/MedicineHospital Sant Pau, UAB, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Barcelona, Spain
| | - Holger Franz
- Lohmann & Birkner Health Care Consulting GmbHBerlin, Germany
| | - Thierry Brue
- Aix-Marseille UniversitéCNRS, CRN2M UMR 7286, Marseille, France
- APHMHôpital Conception, Marseille, France
| | | | | | | | - Susan M Webb
- IIB-Sant Pau and Department of Endocrinology/MedicineHospital Sant Pau, UAB, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Barcelona, Spain
| | | | - Martin Reincke
- Medizinische Klinik und Poliklinik IVCampus Innestadt, Klinikum der Universität München, München, Germany
| | | | - Irina Komerdus
- Moscow Regional Research Clinical Institute n.a. VladimirskyMoscow, Russia
| | | | - Darko Kastelan
- Department of EndocrinologyUniversity Hospital Zagreb, School of Medicine University of Zagreb, Zagreb, Croatia
| | - Philippe Chanson
- Univ Paris-SudUniversité Paris-Saclay UMR-S1185, Paris, France
- Assistance Publique-Hôpitaux de ParisHôpital de Bicêtre, Service de Endocrinologie et des Maladies de la Reproduction, Paris, France
- Institut National de la Santé et de la Recherche Médicale U1185Paris, France
| | - Marija Pfeifer
- Department of EndocrinologyUniversity Medical Centre Ljubljana, Ljubljana Slovenia
| | - Christian J Strasburger
- Division of Clinical EndocrinologyDepartment of Medicine CCM, Charité-Universitätsmedizin, Berlin, Germany
| | - Miklós Tóth
- 2nd Department of MedicineSemmelweis University, Budapest, Hungary
| | - Olivier Chabre
- Service d'Endocrinologie-Diabétologie-NutritionGrenoble Cedex, France
| | - Michal Krsek
- 2nd Department of Medicine3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - Carmen Fajardo
- Department of EndocrinologyHospital Universitario de la Ribera, Alzira, Spain
| | - Marek Bolanowski
- Department of EndocrinologyDiabetology and Isotope Therapy, Wroclaw Medical University, Wroclaw, Poland
| | - Alicia Santos
- IIB-Sant Pau and Department of Endocrinology/MedicineHospital Sant Pau, UAB, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Barcelona, Spain
| | - Peter J Trainer
- Department of EndocrinologyChristie Hospital, Manchester, UK
| | - John A H Wass
- Oxford University Hospital Foundation TrustOxford, UK
| | - Antoine Tabarin
- Centre Hospitalier Universitaire de BordeauxBordeaux, France
| |
Collapse
|
28
|
Tatsi C, Stratakis CA. Neonatal Cushing Syndrome: A Rare but Potentially Devastating Disease. Clin Perinatol 2018; 45:103-118. [PMID: 29406000 PMCID: PMC5806137 DOI: 10.1016/j.clp.2017.10.002] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Neonatal Cushing syndrome (CS) is most commonly caused by exogenous administration of glucocorticoids and rarely by endogenous hypercortisolemia. CS owing to adrenal lesions is the most common cause of endogenous CS in neonates and infants, and adrenocortical tumors (ACTs) represent most cases. Many ACTs develop in the context of a TP53 gene mutation, which causes Li-Fraumeni syndrome. More rarely, neonatal CS presents as part of other syndromes such as McCune-Albright syndrome or Beckwith-Wiedemann syndrome. Management usually includes resection of the primary tumor with or without additional medical treatment, but manifestations may persist after resolution of hypercortisolemia.
Collapse
Affiliation(s)
- Christina Tatsi
- Section on Endocrinology & Genetics, Developmental Endocrine Oncology and Genetics Group, Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD 20892, USA,Pediatric Endocrinology Inter-institute Training Program, Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD 20892, USA
| | - Constantine A. Stratakis
- Section on Endocrinology & Genetics, Developmental Endocrine Oncology and Genetics Group, Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD 20892, USA,Pediatric Endocrinology Inter-institute Training Program, Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD 20892, USA
| |
Collapse
|
29
|
Fuertes M, Tkatch J, Rosmino J, Nieto L, Guitelman MA, Arzt E. New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A. Front Endocrinol (Lausanne) 2018; 9:262. [PMID: 29881371 PMCID: PMC5976796 DOI: 10.3389/fendo.2018.00262] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Accepted: 05/07/2018] [Indexed: 12/19/2022] Open
Abstract
Cushing's disease (CD) is an endocrine disorder originated by a corticotroph tumor. It is linked with high mortality and morbidity due to chronic hypercortisolism. Treatment goals are to control cortisol excess and achieve long-term remission, therefore, reducing both complications and patient's mortality. First-line of treatment for CD is pituitary's surgery. However, 30% of patients who undergo surgery experience recurrence in long-term follow-up. Persistent or recurrent CD demands second-line treatments, such as pituitary radiotherapy, adrenal surgery, and/or pharmacological therapy. The latter plays a key role in cortisol excess control. Its targets are inhibition of adrenocorticotropic hormone (ACTH) production, inhibition of adrenal steroidogenesis, or antagonism of cortisol action at its peripheral receptor. Retinoic acid (RA) is a metabolic product of vitamin A (retinol) and has been studied for its antiproliferative effects on corticotroph tumor cells. It has been shown that this drug regulates the expression of pro-opiomelanocortin (POMC), ACTH secretion, and tumor growth in corticotroph tumor mouse cell lines and in the nude mice experimental model, via inhibition of POMC transcription. It has been shown to result in tumor reduction, normalization of cortisol levels and clinical improvement in dogs treated with RA for 6 months. The orphan nuclear receptor COUP-TFI is expressed in normal corticotroph cells, but not in corticotroph tumoral cells, and inhibits RA pathways. A first clinical human study demonstrated clinical and biochemical effectiveness in 5/7 patients treated with RA for a period of up to 12 months. In a recent second clinical trial, 25% of 16 patients achieved eucortisolemia, and all achieved a cortisol reduction after 6- to 12-month treatment. The goal of this review is to discuss in the context of the available and future pharmacological treatments of CD, RA mechanisms of action on corticotroph tumor cells, and future perspectives, focusing on potential clinical implementation.
Collapse
Affiliation(s)
- Mariana Fuertes
- Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA) – CONICET – Partner Institute of the Max Planck Society, Buenos Aires, Argentina
| | - Julieta Tkatch
- División Endocrinología, Hospital General de Agudos “Carlos G. Durand”, Buenos Aires, Argentina
| | - Josefina Rosmino
- División Endocrinología, Hospital General de Agudos “Carlos G. Durand”, Buenos Aires, Argentina
| | - Leandro Nieto
- Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA) – CONICET – Partner Institute of the Max Planck Society, Buenos Aires, Argentina
| | | | - Eduardo Arzt
- Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA) – CONICET – Partner Institute of the Max Planck Society, Buenos Aires, Argentina
- Departamento de Fisiología y Biología Molecular y Celular, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina
- *Correspondence: Eduardo Arzt,
| |
Collapse
|
30
|
Valassi E, Aulinas A, Glad CA, Johannsson G, Ragnarsson O, Webb SM. A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome. Clin Endocrinol (Oxf) 2017; 87:433-439. [PMID: 28665508 DOI: 10.1111/cen.13414] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Revised: 06/20/2017] [Accepted: 06/28/2017] [Indexed: 12/01/2022]
Abstract
CONTEXT Steroidogenesis inhibitors, such as ketoconazole (KTZ) and metyrapone (MTP), are used to lower hypercortisolism in patients with Cushing's syndrome (CS). Cortisol normalization is not reached in all patients taking these medications. OBJECTIVE To test the hypothesis that variants in genes affecting steroidogenesis contribute to different responses to KTZ and/or MTP in patients with CS. PATIENTS AND METHODS Fifty-four CS patients (46 women; mean [±SD] age, 39.7±12.7; 83% with Cushing's disease [CD] and 17% with an adrenal adenoma) preoperatively treated with KTZ (20%), MTP (37%) or a combination of both (43%). Thirty-nine of these (72%) were described in a previous study investigating the outcome of preoperative treatment with KTZ or MTP in CS patients. Following single-nucleotide polymorphisms (SNPs) were analysed: rs6410 (CYP11B1 gene), rs1799998 and rs4546 (CYP11B2 gene), and rs6163 (CYP17A1 gene). The associations between SNPs and cortisol levels at the end of medical treatment were evaluated. RESULTS Normalization of urinary free cortisol (UFC) was achieved in 50% of patients after 5 months of treatment. Patients carrying the CC genotype of SNP rs6163 were more likely to be controlled than AC/AA (OR 0.25 [95%CI, 0.075-0.88]; P=.031). When only patients reaching eucortisolism after medical treatment were analysed, median interquartile range (IQR) duration of treatment was shorter in patients carrying the CC genotype of SNP rs6163 as compared to AA/AC carriers (4 [4.57] months vs 5.2 [6.1] months; P=.026). CONCLUSIONS A polymorphism in the CYP17A1 gene was associated with the response to steroidogenesis inhibitors in CS. Genetic differences in the steroidogenic enzymes might account for inter-individual variations in the responsiveness to adrenal-blocking agents.
Collapse
Affiliation(s)
- Elena Valassi
- Endocrinology/Medicine Department, Hospital Sant Pau and IIB, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Anna Aulinas
- Endocrinology/Medicine Department, Hospital Sant Pau and IIB, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Camilla Am Glad
- Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Department of Endocrinology-Diabetes-Metabolism, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Gudmundur Johannsson
- Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Department of Endocrinology-Diabetes-Metabolism, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Oskar Ragnarsson
- Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Department of Endocrinology-Diabetes-Metabolism, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Susan M Webb
- Endocrinology/Medicine Department, Hospital Sant Pau and IIB, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| |
Collapse
|
31
|
Abstract
Cushing syndrome (CS) is caused by chronic exposure to excess glucocorticoids. Early recognition and treatment of hypercortisolemia can lead to decreased morbidity and mortality. The diagnosis of CS and thereafter, establishing the cause can often be difficult, especially in patients with mild and cyclic hypercortisolism. Surgical excision of the cause of excess glucocorticoids is the optimal treatment for CS. Medical therapy (steroidogenesis inhibitors, medications that decrease adrenocorticotropic hormone [ACTH] levels or glucocorticoid antagonists) and pituitary radiotherapy may be needed as adjunctive treatment modalities in patients with residual, recurrent or metastatic disease, in preparation for surgery, or when surgery is contraindicated. A multidisciplinary team approach, individualized treatment plan and long-term follow-up are important for optimal management of hypercortisolemia and the comorbidities associated with CS. ABBREVIATIONS ACTH = adrenocorticotropic hormone; BIPSS = bilateral inferior petrosal sinus sampling; CBG = corticosteroid-binding globulin; CD = Cushing disease; CRH = corticotropin-releasing hormone; CS = Cushing syndrome; Dex = dexamethasone; DST = dexamethasone suppression test; EAS = ectopic ACTH syndrome; FDA = U.S. Food & Drug Administration; HDDST = high-dose DST; IPS/P = inferior petrosal sinus to peripheral; MRI = magnetic resonance imaging; NET = neuroendocrine tumor; PET = positron emission tomography; UFC = urinary free cortisol.
Collapse
|
32
|
Sek KSY, Deepak DS, Lee KO. Use of cabergoline for the management of persistent Cushing's disease in pregnancy. BMJ Case Rep 2017; 2017:bcr-2016-217855. [PMID: 28710189 DOI: 10.1136/bcr-2016-217855] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Cushing's disease (CD) is rare during pregnancy and is associated with significant maternal and fetal complications. It is important to control hypercortisolism during pregnancy, either surgically or medically, for a successful maternal and fetal outcome. We report a patient with recurrent CD who was treated with low-dose cabergoline (CAB) for persistent hypercortisolism throughout pregnancy. A 36-year-old woman was diagnosed with CD at the age of 23. She underwent trans-sphenoidal surgery with initial complete remission. However, 4 years after surgery, CD recurred and she underwent Gamma Knife radiosurgery (GKRS). Following GKRS, her cortisol levels remained elevated despite no evidence of visible tumour on pituitary MRI. Medical treatment was commenced with ketoconazole and cyproheptadine. This was changed to CAB as she was keen for pregnancy. She conceived spontaneously and was on CAB throughout pregnancy. She delivered a healthy male neonate, weighing 3195 g at 40 weeks of gestation.
Collapse
Affiliation(s)
| | | | - Kok Onn Lee
- Department of Medicine, National University Hospital, Singapore, Singapore
| |
Collapse
|
33
|
Sek KSY, Deepak DS, Lee KO. Use of cabergoline for the management of persistent Cushing's disease in pregnancy. BMJ Case Rep 2017. [PMID: 28710189 DOI: 10.1136/bcr-2016-217855.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Cushing's disease (CD) is rare during pregnancy and is associated with significant maternal and fetal complications. It is important to control hypercortisolism during pregnancy, either surgically or medically, for a successful maternal and fetal outcome. We report a patient with recurrent CD who was treated with low-dose cabergoline (CAB) for persistent hypercortisolism throughout pregnancy. A 36-year-old woman was diagnosed with CD at the age of 23. She underwent trans-sphenoidal surgery with initial complete remission. However, 4 years after surgery, CD recurred and she underwent Gamma Knife radiosurgery (GKRS). Following GKRS, her cortisol levels remained elevated despite no evidence of visible tumour on pituitary MRI. Medical treatment was commenced with ketoconazole and cyproheptadine. This was changed to CAB as she was keen for pregnancy. She conceived spontaneously and was on CAB throughout pregnancy. She delivered a healthy male neonate, weighing 3195 g at 40 weeks of gestation.
Collapse
Affiliation(s)
| | | | - Kok Onn Lee
- Department of Medicine, National University Hospital, Singapore, Singapore
| |
Collapse
|
34
|
Rathor PK, Bhat IA, Rather MA, Gireesh-Babu P, Kumar K, Purayil SBP, Sharma R. Steroidogenic acute regulatory protein (StAR) gene expression construct: Development, nanodelivery and effect on reproduction in air-breathing catfish, Clarias batrachus. Int J Biol Macromol 2017; 104:1082-1090. [PMID: 28666831 DOI: 10.1016/j.ijbiomac.2017.06.104] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2017] [Revised: 06/24/2017] [Accepted: 06/26/2017] [Indexed: 12/17/2022]
Abstract
Steroidogenic acute regulatory protein (StAR) is responsible for the relocation of cholesterol across mitochondrial membrane in vertebrates and is, therefore, a key factor in regulating the rate and timing of steroidogenesis. In the present study, we developed chitosan nanoparticle (CNP) conjugated StAR gene construct (CNP-pcDNA4-StAR) in a eukaryotic expression vector, pcDNA4/HisMax A. CNPs of 135.4nm diameter, 26.7mV zeta potential and 0.381 polydispersity index were used for conjugation. The loading efficiency (LE) of pcDNA4-StAR construct with CNPs was found to be 86%. After the 24h of intramuscular injection, the CNP-pcDNA4-StAR plasmid could be detected from testis, brain, kidney and muscle tissues of Clarias batrachus. The transcript levels of important reproductive genes viz. cyp11a1, cyp17a1, 3β-hsd, 17β-hsd and cyp19a1 in CNP-pcDNA4-StAR treated group were initially low up to 24h, but significantly increased subsequently up to 120h. In naked pcDNA4-StAR treated group, the mRNA level of 3β-hsd, 17β-hsd and cyp19a1 increased initially up to 24h, while cyp11a1 and cyp17a1 increased up to 48h and then started declining. Similar results were obtained for 11-Ketotestosterone and 17β-estradiol. The results indicate relatively long lasting effects of nano-conjugated construct compared to the construct alone. Furthermore, the histopathology of gonads and liver authenticates its possible role in the gonadal development in fish without any adverse effect.
Collapse
Affiliation(s)
- Pravesh Kumar Rathor
- Division of Fish Genetics and Biotechnology, Central Institute of Fisheries Education, Mumbai, 400061, India
| | - Irfan Ahmad Bhat
- Division of Fish Genetics and Biotechnology, Central Institute of Fisheries Education, Mumbai, 400061, India
| | - Mohd Ashraf Rather
- Department of Fisheries Biology, College of Fisheries Shirgoan, Ratnagiri, 415712 Maharashtra, India
| | - Pathakota Gireesh-Babu
- Division of Fish Genetics and Biotechnology, Central Institute of Fisheries Education, Mumbai, 400061, India
| | - Kundan Kumar
- Division of Aquatic Environmental and Health Management, Central Institute of Fisheries Education, Mumbai, 400061, India
| | | | - Rupam Sharma
- Division of Fish Genetics and Biotechnology, Central Institute of Fisheries Education, Mumbai, 400061, India.
| |
Collapse
|
35
|
Emmerich J, van Koppen CJ, Burkhart JL, Hu Q, Siebenbürger L, Boerger C, Scheuer C, Laschke MW, Menger MD, Hartmann RW. Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing’s Disease. J Med Chem 2017; 60:5086-5098. [DOI: 10.1021/acs.jmedchem.7b00437] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- Juliette Emmerich
- Pharmaceutical
and Medicinal Chemistry, Saarland University, Campus E8.1, 66123 Saarbrücken, Germany
| | | | | | - Qingzhong Hu
- Department
of Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus E8.1, 66123 Saarbrücken, Germany
| | | | - Carsten Boerger
- PharmBioTec GmbH, Science Park 1, 66123 Saarbrücken, Germany
| | - Claudia Scheuer
- Institute
for Clinical and Experimental Surgery, Saarland University, 66421 Homburg, Saar, Germany
| | - Matthias W. Laschke
- Institute
for Clinical and Experimental Surgery, Saarland University, 66421 Homburg, Saar, Germany
| | - Michael D. Menger
- Institute
for Clinical and Experimental Surgery, Saarland University, 66421 Homburg, Saar, Germany
| | - Rolf W. Hartmann
- Pharmaceutical
and Medicinal Chemistry, Saarland University, Campus E8.1, 66123 Saarbrücken, Germany
- Department
of Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus E8.1, 66123 Saarbrücken, Germany
| |
Collapse
|
36
|
Uraki S, Ariyasu H, Doi A, Furuta H, Nishi M, Usui T, Yamaue H, Akamizu T. Hypersecretion of ACTH and PRL from pituitary adenoma in MEN1, adequately managed by medical therapy. Endocrinol Diabetes Metab Case Rep 2017; 2017:EDM170027. [PMID: 28458907 PMCID: PMC5404709 DOI: 10.1530/edm-17-0027] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Accepted: 03/17/2017] [Indexed: 11/17/2022] Open
Abstract
Summary A 54-year-old man had gastrinoma, parathyroid hyperplasia and pituitary tumor. His family history indicated that he might have multiple endocrine neoplasia type 1 (MEN1). MEN1 gene analysis revealed a heterozygous germline mutation (Gly156Arg). Therefore, we diagnosed him with MEN1. Endocrinological tests revealed that his serum prolactin (PRL) and plasma adrenocorticotropic hormone (ACTH) levels were elevated to 1699 ng/mL and 125 pg/mL respectively. Immunohistochemical analysis of the resected pancreatic tumors revealed that the tumors did not express ACTH. Overnight 0.5 and 8 mg dexamethasone suppression tests indicated that his pituitary tumor was a PRL-ACTH-producing plurihormonal tumor. Before transsphenoidal surgery, cabergoline was initiated. Despite no decrease in the volume of the pituitary tumor, PRL and ACTH levels decreased to 37.8 ng/mL and 57.6 pg/mL respectively. Owing to the emergence of metastatic gastrinoma in the liver, octreotide was initiated. After that, PRL and ACTH levels further decreased to 5.1 ng/mL and 19.7 pg/mL respectively. He died from liver dysfunction, and an autopsy of the pituitary tumor was performed. In the autopsy study, histopathological and immunohistochemical (IHC) analysis showed that the tumor was single adenoma and the cells were positive for ACTH, growth hormone (GH), luteinizing hormone (LH) and PRL. RT-PCR analysis showed that the tumor expressed mRNA encoding all anterior pituitary hormones, pituitary transcription factor excluding estrogen receptor (ER) β, somatostatin receptor (SSTR) 2, SSTR5 and dopamine receptor D (D2R). PRL-ACTH-producing tumor is a very rare type of pituitary tumor, and treatment with cabergoline and octreotide may be useful for controlling hormone levels secreted from a plurihormonal pituitary adenoma, as seen in this case of MEN1. Learning points:
Collapse
Affiliation(s)
- Shinsuke Uraki
- The 1st Department of Internal Medicine, Wakayama Medical University, WakayamaJapan
| | - Hiroyuki Ariyasu
- The 1st Department of Internal Medicine, Wakayama Medical University, WakayamaJapan
| | - Asako Doi
- The 1st Department of Internal Medicine, Wakayama Medical University, WakayamaJapan
| | - Hiroto Furuta
- The 1st Department of Internal Medicine, Wakayama Medical University, WakayamaJapan
| | - Masahiro Nishi
- The 1st Department of Internal Medicine, Wakayama Medical University, WakayamaJapan
| | - Takeshi Usui
- Department of Medical Genetics, Shizuoka General Hospital, Shizuoka CityJapan
| | - Hiroki Yamaue
- The 2nd Department of Surgery, Wakayama Medical University, WakayamaJapan
| | - Takashi Akamizu
- The 1st Department of Internal Medicine, Wakayama Medical University, WakayamaJapan
| |
Collapse
|
37
|
Espinosa-de-Los-Monteros AL, Sosa-Eroza E, Espinosa E, Mendoza V, Arreola R, Mercado M. LONG-TERM OUTCOME OF THE DIFFERENT TREATMENT ALTERNATIVES FOR RECURRENT AND PERSISTENT CUSHING DISEASE. Endocr Pract 2017; 23:759-767. [PMID: 28332874 DOI: 10.4158/ep171756.or] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE Treatment alternatives for persistent and recurrent Cushing disease (CD) include pituitary surgical re-intervention, radiation therapy (RT), pharmacotherapy, and bilateral adrenalectomy (BA). The decision of which of these alternatives is better suited for the individual patient rests on clinical judgment and the availability of resources. This retrospective cohort study was performed at a referral center to evaluate the long-term efficacy of different secondary interventions for persistent and recurrent CD. METHODS We evaluated the hospital charts of 84 patients (77 female, median age 34 years, median follow up 6.3 years) with CD diagnosed, treated, and followed at our multidisciplinary clinic according to a pre-established protocol. RESULTS Of the 81 patients who were initially treated with transsphenoidal surgery (TSS), 61.7% had a long-lasting remission, 16% had persistent disease, and 22% achieved remission but relapsed during follow-up. The most frequently used secondary treatment was pituitary re-intervention, followed by ketoconazole, RT, and BA. Early remissions were observed in 66.6% of the re-operated and in 58.3% of the radiated patients; long-lasting remission was achieved in 33.3% and 41.6% of these patients, respectively. Nelson syndrome developed in 41.6% of the patients who underwent BA. Upon last follow-up, 88% of all the patients are in remission, and 9.5% are biochemically controlled with ketoconazole. CONCLUSION The efficacy of treatment alternatives for recurrent or persistent CD varies considerably among patients and multiple interventions are often required to achieve long-lasting remission. ABBREVIATIONS ACTH = adrenocorticotrophic hormone; BA = bilateral adrenalectomy; CBG = cabergoline; CD = Cushing disease; CV = coefficient of variation; DXM = dexamethasone; IQR = interquartile range; RT = radiation therapy; SRS = stereotactic radiosurgery; TSS = transsphenoidal surgery; UFC = urinary free cortisol; ULN = upper limit of normal.
Collapse
|
38
|
Lefkowitz EG, Cossman JP, Fournier JB. A Case Report of Cushing's Disease Presenting as Hair Loss. Case Rep Dermatol 2017; 9:45-50. [PMID: 28413388 PMCID: PMC5346917 DOI: 10.1159/000457898] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2017] [Accepted: 01/23/2017] [Indexed: 12/03/2022] Open
Abstract
Cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. Most cases of Cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as Cushing's disease. Most of the signs and symptoms are nonspecific and common in the general population, making a diagnosis often challenging. However, several dermatological manifestations, such as fragile skin, easy bruising, and reddish purple striae, are more discriminatory. Because uncontrolled Cushing's syndrome of any etiology is associated with substantial morbidity, including increased cardiovascular disease and mortality, it is important to make an early diagnosis. Unfortunately, median delays of 2 years to diagnosis have been reported. We report a case of a woman who had multiple dermatological findings, including facial plethora, easy bruising, violaceous striae, hirsutism, and acne, the latter 2 signs reflecting androgen excess. Of interest, our patient presented with a chief complaint of hair loss, a common complaint in the general population that occurs with a greater frequency in patients with Cushing's disease and is attributed to androgenetic alopecia, but it is rarely the presenting symptom.
Collapse
Affiliation(s)
| | - Jack P Cossman
- Department of Dermatology, Roger Williams Medical Center, Providence, RI, USA
| | - John B Fournier
- Department of Dermatology, Roger Williams Medical Center, Providence, RI, USA.,Department of Dermatology, Boston University School of Medicine, Boston, MA, USA.,Inpatient Dermatology Consultative Service, Roger Williams Medical Center, Providence, RI, USA
| |
Collapse
|
39
|
Oster H, Challet E, Ott V, Arvat E, de Kloet ER, Dijk DJ, Lightman S, Vgontzas A, Van Cauter E. The Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids. Endocr Rev 2017; 38:3-45. [PMID: 27749086 PMCID: PMC5563520 DOI: 10.1210/er.2015-1080] [Citation(s) in RCA: 294] [Impact Index Per Article: 42.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/27/2015] [Accepted: 09/21/2016] [Indexed: 02/07/2023]
Abstract
Adrenal glucocorticoids are major modulators of multiple functions, including energy metabolism, stress responses, immunity, and cognition. The endogenous secretion of glucocorticoids is normally characterized by a prominent and robust circadian (around 24 hours) oscillation, with a daily peak around the time of the habitual sleep-wake transition and minimal levels in the evening and early part of the night. It has long been recognized that this 24-hour rhythm partly reflects the activity of a master circadian pacemaker located in the suprachiasmatic nucleus of the hypothalamus. In the past decade, secondary circadian clocks based on the same molecular machinery as the central master pacemaker were found in other brain areas as well as in most peripheral tissues, including the adrenal glands. Evidence is rapidly accumulating to indicate that misalignment between central and peripheral clocks has a host of adverse effects. The robust rhythm in circulating glucocorticoid levels has been recognized as a major internal synchronizer of the circadian system. The present review examines the scientific foundation of these novel advances and their implications for health and disease prevention and treatment.
Collapse
Affiliation(s)
- Henrik Oster
- Medical Department I (H.O., V.O.), University of Lübeck, 23562 Lübeck, Germany; Institute for Cellular and Integrative Neuroscience (E.C.), Centre National de la Recherche Scientifique (CNRS) UPR 3212, University of Strasbourg, 67084 Strasbourg, France; Division of Endocrinology, Diabetology and Metabolism (E.A.), Department of Internal Medicine, University of Turin, 10043 Turin, Italy; Department of Endocrinology and Metabolic Disease (E.R.d.K.), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; Surrey Sleep Research Center (D.-J.D.), Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XP, United Kingdom; Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology (S.L.), University of Bristol, Bristol BS8 1TH, United Kingdom; Sleep Research and Treatment Center (A.V.), Department of Psychiatry, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033; and Sleep, Metabolism, and Health Center (E.V.C.), Department of Medicine, University of Chicago, Chicago, Illinois 60637
| | - Etienne Challet
- Medical Department I (H.O., V.O.), University of Lübeck, 23562 Lübeck, Germany; Institute for Cellular and Integrative Neuroscience (E.C.), Centre National de la Recherche Scientifique (CNRS) UPR 3212, University of Strasbourg, 67084 Strasbourg, France; Division of Endocrinology, Diabetology and Metabolism (E.A.), Department of Internal Medicine, University of Turin, 10043 Turin, Italy; Department of Endocrinology and Metabolic Disease (E.R.d.K.), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; Surrey Sleep Research Center (D.-J.D.), Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XP, United Kingdom; Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology (S.L.), University of Bristol, Bristol BS8 1TH, United Kingdom; Sleep Research and Treatment Center (A.V.), Department of Psychiatry, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033; and Sleep, Metabolism, and Health Center (E.V.C.), Department of Medicine, University of Chicago, Chicago, Illinois 60637
| | - Volker Ott
- Medical Department I (H.O., V.O.), University of Lübeck, 23562 Lübeck, Germany; Institute for Cellular and Integrative Neuroscience (E.C.), Centre National de la Recherche Scientifique (CNRS) UPR 3212, University of Strasbourg, 67084 Strasbourg, France; Division of Endocrinology, Diabetology and Metabolism (E.A.), Department of Internal Medicine, University of Turin, 10043 Turin, Italy; Department of Endocrinology and Metabolic Disease (E.R.d.K.), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; Surrey Sleep Research Center (D.-J.D.), Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XP, United Kingdom; Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology (S.L.), University of Bristol, Bristol BS8 1TH, United Kingdom; Sleep Research and Treatment Center (A.V.), Department of Psychiatry, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033; and Sleep, Metabolism, and Health Center (E.V.C.), Department of Medicine, University of Chicago, Chicago, Illinois 60637
| | - Emanuela Arvat
- Medical Department I (H.O., V.O.), University of Lübeck, 23562 Lübeck, Germany; Institute for Cellular and Integrative Neuroscience (E.C.), Centre National de la Recherche Scientifique (CNRS) UPR 3212, University of Strasbourg, 67084 Strasbourg, France; Division of Endocrinology, Diabetology and Metabolism (E.A.), Department of Internal Medicine, University of Turin, 10043 Turin, Italy; Department of Endocrinology and Metabolic Disease (E.R.d.K.), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; Surrey Sleep Research Center (D.-J.D.), Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XP, United Kingdom; Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology (S.L.), University of Bristol, Bristol BS8 1TH, United Kingdom; Sleep Research and Treatment Center (A.V.), Department of Psychiatry, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033; and Sleep, Metabolism, and Health Center (E.V.C.), Department of Medicine, University of Chicago, Chicago, Illinois 60637
| | - E Ronald de Kloet
- Medical Department I (H.O., V.O.), University of Lübeck, 23562 Lübeck, Germany; Institute for Cellular and Integrative Neuroscience (E.C.), Centre National de la Recherche Scientifique (CNRS) UPR 3212, University of Strasbourg, 67084 Strasbourg, France; Division of Endocrinology, Diabetology and Metabolism (E.A.), Department of Internal Medicine, University of Turin, 10043 Turin, Italy; Department of Endocrinology and Metabolic Disease (E.R.d.K.), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; Surrey Sleep Research Center (D.-J.D.), Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XP, United Kingdom; Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology (S.L.), University of Bristol, Bristol BS8 1TH, United Kingdom; Sleep Research and Treatment Center (A.V.), Department of Psychiatry, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033; and Sleep, Metabolism, and Health Center (E.V.C.), Department of Medicine, University of Chicago, Chicago, Illinois 60637
| | - Derk-Jan Dijk
- Medical Department I (H.O., V.O.), University of Lübeck, 23562 Lübeck, Germany; Institute for Cellular and Integrative Neuroscience (E.C.), Centre National de la Recherche Scientifique (CNRS) UPR 3212, University of Strasbourg, 67084 Strasbourg, France; Division of Endocrinology, Diabetology and Metabolism (E.A.), Department of Internal Medicine, University of Turin, 10043 Turin, Italy; Department of Endocrinology and Metabolic Disease (E.R.d.K.), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; Surrey Sleep Research Center (D.-J.D.), Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XP, United Kingdom; Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology (S.L.), University of Bristol, Bristol BS8 1TH, United Kingdom; Sleep Research and Treatment Center (A.V.), Department of Psychiatry, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033; and Sleep, Metabolism, and Health Center (E.V.C.), Department of Medicine, University of Chicago, Chicago, Illinois 60637
| | - Stafford Lightman
- Medical Department I (H.O., V.O.), University of Lübeck, 23562 Lübeck, Germany; Institute for Cellular and Integrative Neuroscience (E.C.), Centre National de la Recherche Scientifique (CNRS) UPR 3212, University of Strasbourg, 67084 Strasbourg, France; Division of Endocrinology, Diabetology and Metabolism (E.A.), Department of Internal Medicine, University of Turin, 10043 Turin, Italy; Department of Endocrinology and Metabolic Disease (E.R.d.K.), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; Surrey Sleep Research Center (D.-J.D.), Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XP, United Kingdom; Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology (S.L.), University of Bristol, Bristol BS8 1TH, United Kingdom; Sleep Research and Treatment Center (A.V.), Department of Psychiatry, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033; and Sleep, Metabolism, and Health Center (E.V.C.), Department of Medicine, University of Chicago, Chicago, Illinois 60637
| | - Alexandros Vgontzas
- Medical Department I (H.O., V.O.), University of Lübeck, 23562 Lübeck, Germany; Institute for Cellular and Integrative Neuroscience (E.C.), Centre National de la Recherche Scientifique (CNRS) UPR 3212, University of Strasbourg, 67084 Strasbourg, France; Division of Endocrinology, Diabetology and Metabolism (E.A.), Department of Internal Medicine, University of Turin, 10043 Turin, Italy; Department of Endocrinology and Metabolic Disease (E.R.d.K.), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; Surrey Sleep Research Center (D.-J.D.), Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XP, United Kingdom; Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology (S.L.), University of Bristol, Bristol BS8 1TH, United Kingdom; Sleep Research and Treatment Center (A.V.), Department of Psychiatry, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033; and Sleep, Metabolism, and Health Center (E.V.C.), Department of Medicine, University of Chicago, Chicago, Illinois 60637
| | - Eve Van Cauter
- Medical Department I (H.O., V.O.), University of Lübeck, 23562 Lübeck, Germany; Institute for Cellular and Integrative Neuroscience (E.C.), Centre National de la Recherche Scientifique (CNRS) UPR 3212, University of Strasbourg, 67084 Strasbourg, France; Division of Endocrinology, Diabetology and Metabolism (E.A.), Department of Internal Medicine, University of Turin, 10043 Turin, Italy; Department of Endocrinology and Metabolic Disease (E.R.d.K.), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; Surrey Sleep Research Center (D.-J.D.), Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XP, United Kingdom; Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology (S.L.), University of Bristol, Bristol BS8 1TH, United Kingdom; Sleep Research and Treatment Center (A.V.), Department of Psychiatry, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033; and Sleep, Metabolism, and Health Center (E.V.C.), Department of Medicine, University of Chicago, Chicago, Illinois 60637
| |
Collapse
|
40
|
Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas. PLoS One 2016; 11:e0169009. [PMID: 28005997 PMCID: PMC5179081 DOI: 10.1371/journal.pone.0169009] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Accepted: 12/09/2016] [Indexed: 11/19/2022] Open
Abstract
Purpose Cushing’s disease (CD), also known as pituitary-dependent hyperadrenocorticism, is caused by adrenocorticotropic hormone (ACTH)-secreting pituitary tumours. Affected humans and dogs have similar clinical manifestations, however, the incidence of the canine disease is thousand-fold higher. This makes the dog an obvious model for studying the pathogenesis of pituitary-dependent hyperadrenocorticism. Despite certain similarities identified at the molecular level, the question still remains whether the two species have a shared oncogenetic background. Recently, hotspot recurrent mutations in the gene encoding for ubiquitin specific protease 8 (USP8) have been identified as the main driver behind the formation of ACTH-secreting pituitary adenomas in humans. In this study, we aimed to verify whether USP8 mutations also play a role in the development of such tumours in dogs. Methods Presence of USP8 mutations was analysed by Sanger and PCR-cloning sequencing in 38 canine ACTH-secreting adenomas. Furthermore, the role of USP8 and EGFR protein expression was assessed by immunohistochemistry in a subset of 25 adenomas. Results None of the analysed canine ACTH-secreting adenomas presented mutations in the USP8 gene. In a subset of these adenomas, however, we observed an increased nuclear expression of USP8, a phenotype characteristic for the USP8 mutated human tumours, that correlated with smaller tumour size but elevated ACTH production in those tumours. Conclusions Canine ACTH-secreting pituitary adenomas lack mutations in the USP8 gene suggesting a different genetic background of pituitary tumourigenesis in dogs. However, elevated nuclear USP8 protein expression in a subset of tumours was associated with a similar phenotype as in their human counterparts, indicating a possible end-point convergence of the different genetic backgrounds in the two species. In order to establish the dog as a useful animal model for the study of CD, further comprehensive studies are needed.
Collapse
|
41
|
Ciato D, Mumbach AG, Paez-Pereda M, Stalla GK. Currently used and investigational drugs for Cushing´s disease. Expert Opin Investig Drugs 2016; 26:75-84. [PMID: 27894193 DOI: 10.1080/13543784.2017.1266338] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
INTRODUCTION Cushing's disease (CD) is caused by a corticotroph adenoma of the pituitary gland that secretes excess adrenocorticotropic hormone (ACTH) causing increased morbidity and mortality. Surgery is the treatment of choice, but is not always successful. Alternatives include radiotherapy, adrenal surgery, and pharmaceutical therapy. The latter is increasingly gaining momentum due to the recent development of compounds that reduce hypercortisolaemia or its symptoms, acting through different mechanisms. Areas covered: In this article, the authors provide a complete overview of the treatment options for Cushing´s disease, including adrenal-directed, tumor-targeted, and peripheral therapies that are currently used or in development, and discuss their potential advantages and limitations. Expert opinion: Considering the lack of long-term remission in up to half of the patients after surgery, and the delayed response to radiotherapy along with potential side effects, there is a strong need for an effective pharmaceutical treatment. Pasireotide, mifepristone, ketoconazole and metyrapone have been approved by regulatory authorities but their use remains limited due to considerable costs and side effects. Research in this field has focused recently on the improvement of pre-existing drugs and the development of safe new ones. However, few approaches aim at targeting the source of the disease, the ACTH-secreting adenoma.
Collapse
Affiliation(s)
- Denis Ciato
- a Clinical Neuroendocrinology , Max Planck Institute of Psychiatry , Munich , Germany.,b Endocrinology Division, Department of Medicine , University-Hospital of Padua , Padua , Italy
| | - Aizhar G Mumbach
- c Endocrinology Division , Carlos G. Durand Hospital , Buenos Aires , Argentina
| | - Marcelo Paez-Pereda
- a Clinical Neuroendocrinology , Max Planck Institute of Psychiatry , Munich , Germany
| | - Günter K Stalla
- a Clinical Neuroendocrinology , Max Planck Institute of Psychiatry , Munich , Germany
| |
Collapse
|
42
|
Abstract
PURPOSE Endogenous Cushing's syndrome (CS) is a rare disease that results from exposure to high levels of cortisol; Cushing's disease (CD) is the most frequent form of CS. Patients with CS suffer from a variety of comorbidities that increase the risk of mortality. Surgical resection of the disease-causing lesion is generally the first-line treatment of CS. However, some patients may not be eligible for surgery due to comorbidities, and approximately 25 % of patients, especially those with CD, have recurrent disease. For these patients, adrenal steroidogenesis inhibitors may control cortisol elevation and subsequent symptomatology. CS is rare overall, and clinical studies of adrenal steroidogenesis inhibitors are often small and, in many cases, data are limited regarding the efficacy and safety of these treatments. Our aim was to better characterize the profiles of efficacy and safety of currently available adrenal steroidogenesis inhibitors, including drugs currently in development. METHODS We performed a systematic review of the literature regarding adrenal steroidogenesis inhibitors, focusing on novel drugs. RESULTS Currently available adrenal steroidogenesis inhibitors, including ketoconazole, metyrapone, etomidate, and mitotane, have variable efficacy and significant side effects, and none are approved by the US Food and Drug Administration for CS. Therefore, there is a clear need for novel, prospectively studied agents that have greater efficacy and a low rate of adverse side effects. Efficacy and safety data of current and emerging adrenal steroidogenesis inhibitors, including osilodrostat (LCI699) and levoketoconazole (COR-003), show promising results that will have to be confirmed in larger-scale phase 3 studies (currently ongoing). CONCLUSIONS The management of CS, and particularly CD, remains challenging. Adrenal steroidogenesis inhibitors can be of major interest to control the hypercortisolism at any time point, either before or after surgery, as discussed in this review.
Collapse
Affiliation(s)
- Maria Fleseriu
- Departments of Medicine and Neurological Surgery, and Northwest Pituitary Center, Oregon Health & Science University, Mail Code: CH8N, 3303 SW Bond Ave, Portland, OR, 97239, USA.
| | - Frederic Castinetti
- Aix Marseille University, CNRS, CRN2M, Department of Endocrinology, Assistance Publique Hopitaux de Marseille, Marseille, France
| |
Collapse
|
43
|
The risks of overlooking the diagnosis of secreting pituitary adenomas. Orphanet J Rare Dis 2016; 11:135. [PMID: 27716353 PMCID: PMC5052978 DOI: 10.1186/s13023-016-0516-x] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2016] [Accepted: 09/16/2016] [Indexed: 01/06/2023] Open
Abstract
Secreting pituitary adenomas that cause acromegaly and Cushing’s disease, as well as prolactinomas and thyrotroph adenomas, are uncommon, usually benign, slow-growing tumours. The rarity of these conditions means that their diagnosis is not familiar to most non-specialist physicians. Consequently, pituitary adenomas may be overlooked and remain untreated, and affected individuals may develop serious comorbidities that reduce their quality of life and life expectancy. Because many signs and symptoms of pituitary adenomas overlap with those of other, more common disorders, general practitioners and non-endocrinology specialists need to be aware of the “red flags” suggestive of these conditions. A long duration of active disease in patients with secreting pituitary adenomas is associated with an increased risk of comorbidities and reduced quality of life. Appropriate treatment can lead to disease remission, and, although some symptoms may persist in some patients, treatment usually reduces the incidence and severity of comorbidities and improves quality of life. Therefore, correct, early diagnosis and characterization of a pituitary adenoma is crucial for patients, to trigger timely, appropriate treatment and to optimize outcome. This article provides an overview of the epidemiology of hormonal syndromes associated with pituitary adenomas, discusses the difficulties of and considerations for their diagnosis, and reviews the comorbidities that may develop, but can be prevented, by accurate diagnosis and appropriate treatment. We hope this review will help general practitioners and non-endocrinology specialists to suspect secreting pituitary adenomas and refer patients to an endocrinologist for confirmation of the diagnosis and treatment.
Collapse
|
44
|
Cuevas-Ramos D, Lim DST, Fleseriu M. Update on medical treatment for Cushing's disease. Clin Diabetes Endocrinol 2016; 2:16. [PMID: 28702250 PMCID: PMC5471955 DOI: 10.1186/s40842-016-0033-9] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/10/2016] [Accepted: 08/25/2016] [Indexed: 12/30/2022] Open
Abstract
Cushing's disease (CD) is the most common cause of endogenous Cushing's syndrome (CS). The goal of treatment is to rapidly control cortisol excess and achieve long-term remission, to reverse the clinical features and reduce long-term complications associated with increased mortality. While pituitary surgery remains first line therapy, pituitary radiotherapy and bilateral adrenalectomy have traditionally been seen as second-line therapies for persistent hypercortisolism. Medical therapy is now recognized to play a key role in the control of cortisol excess. In this review, all currently available medical therapies are summarized, and novel medical therapies in phase 3 clinical trials, such as osilodrostat and levoketoconazole are discussed, with an emphasis on indications, efficacy and safety. Emerging data suggests increased efficacy and better tolerability with these novel therapies and combination treatment strategies, and potentially increases the therapeutic options for treatment of CD. New insights into the pathophysiology of CD are highlighted, along with potential therapeutic applications. Future treatments on the horizon such as R-roscovitine, retinoic acid, epidermal growth factor receptor inhibitors and somatostatin-dopamine chimeric compounds are also described, with a focus on potential clinical utility.
Collapse
Affiliation(s)
- Daniel Cuevas-Ramos
- Department of Endocrinology and Metabolism, Neuroendocrinology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Sección XVI, Tlalpan, Mexico City, 14030 Mexico
| | - Dawn Shao Ting Lim
- Departments of Medicine (Endocrinology) and Neurological Surgery, and Northwest Pituitary Center, Oregon Health & Science University, 3303 SW Bond Ave, Mail Code CH8N, Portland, OR 97239 USA
| | - Maria Fleseriu
- Departments of Medicine (Endocrinology) and Neurological Surgery, and Northwest Pituitary Center, Oregon Health & Science University, 3303 SW Bond Ave, Mail Code CH8N, Portland, OR 97239 USA
| |
Collapse
|
45
|
Morgan SA, Hassan-Smith ZK, Lavery GG. MECHANISMS IN ENDOCRINOLOGY: Tissue-specific activation of cortisol in Cushing's syndrome. Eur J Endocrinol 2016; 175:R83-9. [PMID: 26957494 DOI: 10.1530/eje-15-1237] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/05/2016] [Accepted: 03/07/2016] [Indexed: 12/26/2022]
Abstract
Glucocorticoids are widely prescribed for their anti-inflammatory properties, but have 'Cushingoid' side effects including visceral obesity, muscle myopathy, hypertension, insulin resistance, type 2 diabetes mellitus, osteoporosis, and hepatic steatosis. These features are replicated in patients with much rarer endogenous glucocorticoid (GC) excess (Cushing's syndrome), which has devastating consequences if left untreated. Current medical therapeutic options that reverse the tissue-specific consequences of hypercortisolism are limited. In this article, we review the current evidence that local GC metabolism via the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) plays a central role in mediating the adverse metabolic complications associated with circulatory GC excess - challenging our current view that simple delivery of active GCs from the circulation represents the most important mode of GC action. Furthermore, we explore the potential for targeting this enzyme as a novel therapeutic strategy for the treatment of both endogenous and exogenous Cushing's syndrome.
Collapse
Affiliation(s)
- Stuart A Morgan
- Institute of Metabolism and Systems ResearchInstitute of Biomedical Research, University of Birmingham, Birmingham, UK Centre for Endocrinology Diabetes and MetabolismBirmingham Health Partners, University of Birmingham, Birmingham, UK
| | - Zaki K Hassan-Smith
- Institute of Metabolism and Systems ResearchInstitute of Biomedical Research, University of Birmingham, Birmingham, UK Centre for Endocrinology Diabetes and MetabolismBirmingham Health Partners, University of Birmingham, Birmingham, UK
| | - Gareth G Lavery
- Institute of Metabolism and Systems ResearchInstitute of Biomedical Research, University of Birmingham, Birmingham, UK Centre for Endocrinology Diabetes and MetabolismBirmingham Health Partners, University of Birmingham, Birmingham, UK
| |
Collapse
|
46
|
Cannavo S, Messina E, Albani A, Ferrau F, Barresi V, Priola S, Esposito F, Angileri F. Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide. Endocrine 2016; 52:481-7. [PMID: 25877016 DOI: 10.1007/s12020-015-0601-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Accepted: 04/07/2015] [Indexed: 12/11/2022]
Abstract
The management of critically ill Cushing's disease (CD) patients is extremely challenging. Pasireotide is indicated for the treatment of CD patients when pituitary surgery is unfeasible or has not been curative, but no data are available about the use of this drug as pre-operative treatment in critically ill patients. We report the effects of presurgical pasireotide therapy in CD patients in whom hypercortisolism caused life-threatening hypokalemia, alkalosis, and cardio-respiratory complications precluding surgical approach. Clinical, biochemical, and radiological data of two critically ill patients with ACTH-secreting pituitary macroadenoma, before and during first-line presurgical pasireotide treatment (600 μg s.c. bid). During the first 21 days of treatment, pasireotide therapy induced a rapid, partial decrease of plasma ACTH, serum cortisol, and urinary free cortisol levels, with the consequent normalization of serum potassium concentration and arterial blood gases parameters, in both the patients. They did not experience unmanageable side effects and underwent endoscopic transsphenoidal surgery after 4 weeks of effective treatment. Pre-operative MRI evaluation did not show pituitary tumor shrinkage. Surgical cure of CD was obtained in the first patient, while debulking allowed the pharmacological control of hypercortisolism in the second case. We suggest that pasireotide can induce a rapid improvement of clinical and metabolic conditions in critically ill CD patients in whom surgical approach is considered hazardous and need to be delayed.
Collapse
Affiliation(s)
- S Cannavo
- Department of Clinical and Experimental Medicine - Endocrinology Unit, University of Messina, Messina, Italy
| | - E Messina
- Department of Clinical and Experimental Medicine - Endocrinology Unit, University of Messina, Messina, Italy
| | - A Albani
- Department of Clinical and Experimental Medicine - Endocrinology Unit, University of Messina, Messina, Italy
| | - F Ferrau
- Department of Clinical and Experimental Medicine - Endocrinology Unit, University of Messina, Messina, Italy.
| | - V Barresi
- Department of Human Pathology Gaetano Barresi - Section of Anatomic Pathology, University of Messina, Messina, Italy
| | - S Priola
- Department of Neuroscience - Neurosurgery Unit, University of Messina, Messina, Italy
| | - F Esposito
- Department of Neuroscience - Neurosurgery Unit, University of Messina, Messina, Italy
| | - F Angileri
- Department of Neuroscience - Neurosurgery Unit, University of Messina, Messina, Italy
| |
Collapse
|
47
|
Luque RM, Ibáñez-Costa A, Sánchez-Tejada L, Rivero-Cortés E, Robledo M, Madrazo-Atutxa A, Mora M, Álvarez CV, Lucas-Morante T, Álvarez-Escolá C, Fajardo C, Castaño L, Gaztambide S, Venegas-Moreno E, Soto-Moreno A, Gálvez MÁ, Salvador J, Valassi E, Webb SM, Picó A, Puig-Domingo M, Gilabert M, Bernabéu I, Marazuela M, Leal-Cerro A, Castaño JP. The Molecular Registry of Pituitary Adenomas (REMAH): A bet of Spanish Endocrinology for the future of individualized medicine and translational research. ENDOCRINOLOGIA Y NUTRICION : ORGANO DE LA SOCIEDAD ESPANOLA DE ENDOCRINOLOGIA Y NUTRICION 2016; 63:274-84. [PMID: 27091627 DOI: 10.1016/j.endonu.2016.03.001] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2015] [Revised: 02/17/2016] [Accepted: 03/07/2016] [Indexed: 12/13/2022]
Abstract
Pituitary adenomas are uncommon, difficult to diagnose tumors whose heterogeneity and low incidence complicate large-scale studies. The Molecular Registry of Pituitary Adenomas (REMAH) was promoted by the Andalusian Society of Endocrinology and Nutrition (SAEN) in 2008 as a cooperative clinical-basic multicenter strategy aimed at improving diagnosis and treatment of pituitary adenomas by combining clinical, pathological, and molecular information. In 2010, the Spanish Society of Endocrinology and Nutrition (SEEN) extended this project to national level and established 6 nodes with common protocols and methods for sample and clinical data collection, molecular analysis, and data recording in a common registry (www.remahnacional.com). The registry combines clinical data with molecular phenotyping of the resected pituitary adenoma using quantitative real-time PCR of expression of 26 genes: Pituitary hormones (GH-PRL-LH-FSH-PRL-ACTH-CGA), receptors (somatostatin, dopamine, GHRH, GnRH, CRH, arginine-vasopressin, ghrelin), other markers (Ki67, PTTG1), and control genes. Until 2015, molecular information has been collected from 704 adenomas, out of 1179 patients registered. This strategy allows for comparative and relational analysis between the molecular profile of the different types of adenoma and the clinical phenotype of patients, which may provide a better understanding of the condition and potentially help in treatment selection. The REMAH is therefore a unique multicenter, interdisciplinary network founded on a shared database that provides a far-reaching translational approach for management of pituitary adenomas, and paves the way for the conduct of combined clinical-basic innovative studies on large patient samples.
Collapse
Affiliation(s)
- Raúl M Luque
- Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC); Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba; Hospital Universitario Reina Sofía; Campus de Excelencia Internacional Agroalimentario (ceiA3); CIBER Fisiopatología de la Obesidad y Nutrición, Córdoba, España
| | - Alejandro Ibáñez-Costa
- Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC); Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba; Hospital Universitario Reina Sofía; Campus de Excelencia Internacional Agroalimentario (ceiA3); CIBER Fisiopatología de la Obesidad y Nutrición, Córdoba, España
| | - Laura Sánchez-Tejada
- Departamento de Endocrinología, Hospital General Universitario de Alicante, Alicante, España
| | - Esther Rivero-Cortés
- Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC); Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba; Hospital Universitario Reina Sofía; Campus de Excelencia Internacional Agroalimentario (ceiA3); CIBER Fisiopatología de la Obesidad y Nutrición, Córdoba, España
| | - Mercedes Robledo
- Grupo de Cáncer Endocrino Hereditario, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, España
| | - Ainara Madrazo-Atutxa
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Sevilla, España
| | - Mireia Mora
- Unidad de Endocrinología, Hospital Clinic i Universitari de Barcelona, Barcelona, España
| | - Clara V Álvarez
- Grupo de Neoplasia y Diferenciación Endocrina, Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Instituto de Investigaciones Sanitarias; Facultad de Medicina, Universidad de Santiago de Compostela, Santiago de Compostela, España
| | - Tomás Lucas-Morante
- Servicio de Endocrinología y Nutrición, Hospital Universitario Puerta de Hierro, Madrid, España
| | - Cristina Álvarez-Escolá
- Servicio de Endocrinología y Nutrición, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Madrid, España
| | - Carmen Fajardo
- Servicio de Endocrinología, Hospital Universitario de La Ribera, Alzira, España
| | - Luis Castaño
- Grupo de Investigación de Endocrinología y Diabetes, Hospital Universitario de Cruces, Barakaldo, España
| | - Sonia Gaztambide
- Departamento de Endocrinología y Nutrición, Hospital Universitario de Cruces, Barakaldo, España
| | - Eva Venegas-Moreno
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Sevilla, España
| | - Alfonso Soto-Moreno
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Sevilla, España
| | - María Ángeles Gálvez
- Servicio de Endocrinología y Nutrición, Hospital Universitario Reina Sofía; Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, España
| | - Javier Salvador
- Departamento de Endocrinología y Nutrición, Clínica Universidad de Navarra, Universidad de Navarra; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, España
| | - Elena Valassi
- Institut d'Investigació Biomèdica Sant Pau, Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBER-ER, Unidad 747), Instituto de Salud Carlos III, Barcelona, España
| | - Susan M Webb
- Institut d'Investigació Biomèdica Sant Pau, Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBER-ER, Unidad 747), Instituto de Salud Carlos III, Barcelona, España; Servicio de Endocrinología, Departamento de Medicina, Institut d'Investigació Biomèdica Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España
| | - Antonio Picó
- Departamento de Endocrinología, Hospital General Universitario de Alicante, Alicante, España
| | - Manel Puig-Domingo
- Departamento de Endocrinología y Nutrición, Hospital Universitari Germans Trias i Pujol; Centro de Investigación Biomédica en Enfermedades Raras (CIBER-ER), Badalona, España
| | | | - Ignacio Bernabéu
- Servicio de Endocrinología y Nutrición, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, España
| | - Mónica Marazuela
- Servicio de Endocrinología y Nutrición, Hospital Universitario de La Princesa, Madrid, España
| | - Alfonso Leal-Cerro
- Laboratorio de Endocrinología, IBiS, Hospital Universitario Virgen del Rocío, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Sevilla, España.
| | - Justo P Castaño
- Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC); Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba; Hospital Universitario Reina Sofía; Campus de Excelencia Internacional Agroalimentario (ceiA3); CIBER Fisiopatología de la Obesidad y Nutrición, Córdoba, España.
| |
Collapse
|
48
|
Burton T, Le Nestour E, Neary M, Ludlam WH. Algorithm development and the clinical and economic burden of Cushing's disease in a large US health plan database. Pituitary 2016; 19:167-74. [PMID: 26667029 PMCID: PMC4799236 DOI: 10.1007/s11102-015-0695-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
PURPOSE This study aimed to develop an algorithm to identify patients with CD, and quantify the clinical and economic burden that patients with CD face compared to CD-free controls. METHODS A retrospective cohort study of CD patients was conducted in a large US commercial health plan database between 1/1/2007 and 12/31/2011. A control group with no evidence of CD during the same time was matched 1:3 based on demographics. Comorbidity rates were compared using Poisson and health care costs were compared using robust variance estimation. RESULTS A case-finding algorithm identified 877 CD patients, who were matched to 2631 CD-free controls. The age and sex distribution of the selected population matched the known epidemiology of CD. CD patients were found to have comorbidity rates that were two to five times higher and health care costs that were four to seven times higher than CD-free controls. CONCLUSION An algorithm based on eight pituitary conditions and procedures appeared to identify CD patients in a claims database without a unique diagnosis code. Young CD patients had high rates of comorbidities that are more commonly observed in an older population (e.g., diabetes, hypertension, and cardiovascular disease). Observed health care costs were also high for CD patients compared to CD-free controls, but may have been even higher if the sample had included healthier controls with no health care use as well. Earlier diagnosis, improved surgery success rates, and better treatments may all help to reduce the chronic comorbidity and high health care costs associated with CD.
Collapse
Affiliation(s)
- Tanya Burton
- Optum, 950 Winter Street, Waltham, MA, 02451, USA.
| | | | - Maureen Neary
- Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936, USA
| | - William H Ludlam
- Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936, USA
| |
Collapse
|
49
|
Abalem MF, Machado MC, Santos HNVD, Garcia R, Helal J, Carricondo PC, Pimentel SLG, Monteiro MLR, Qian CX, Bronstein MD, Fragoso MCVB. Choroidal and Retinal Abnormalities by Optical Coherence Tomography in Endogenous Cushing's Syndrome. Front Endocrinol (Lausanne) 2016; 7:154. [PMID: 28018289 PMCID: PMC5145875 DOI: 10.3389/fendo.2016.00154] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2016] [Accepted: 11/28/2016] [Indexed: 11/13/2022] Open
Abstract
CONTEXT Cortisol has been suggested as a risk factor for choroidal thickening, which may lead to retinal changes. OBJECTIVE To compare choroidal thickness measurements using optical coherence tomography (OCT) in patients with endogenous active Cushing's syndrome (CS) and to evaluate the occurrence of retinal abnormalities in the same group of patients. DESIGN Cross-sectional study. SETTING Outpatient clinic. PATIENTS Eleven female patients with CS in hypercortisolism state as determined by the presence of at least two abnormal measurements from urinary cortisol 24 h, no suppression of cortisol with low dose dexamethasone suppression test, and nocturnal salivary cortisol levels and 12 healthy controls. METHODS Choroidal and retinal morphology was assessed using OCT. MAIN OUTCOME MEASURES Choroidal thickness measurements and the presence of retinal changes. RESULTS The mean subfoveal choroidal thickness was 372.96 ± 73.14 µm in the patients with CS and 255.63 ± 50.70 µm in the control group (p < 0.001). One patient (9.09%) presented with central serous chorioretinopathy and one patient (9.09%) with pachychoroid pigment epitheliopathy. CONCLUSION Choroidal thickness is increased in the eyes of patients with active CS compared to healthy and matched control. Also, 18.18% of patients presented with macular changes, possibly secondary to choroidal thickening. While further studies are necessary to confirm our findings, excess corticosteroid levels seem to have a significant effect on the choroid and might be associated with secondary retinal diseases.
Collapse
Affiliation(s)
- Maria Fernanda Abalem
- Department of Ophthalmology and Otolaryngology, University of São Paulo Medical School, São Paulo, São Paulo, Brazil
- Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA
| | - Marcio Carlos Machado
- Department of Endocrinology, University of São Paulo Medical School, São Paulo, São Paulo, Brazil
- Endocrinology Service, AC Camargo Cancer Center, São Paulo, São Paulo, Brazil
| | | | - Rafael Garcia
- Department of Ophthalmology and Otolaryngology, University of São Paulo Medical School, São Paulo, São Paulo, Brazil
| | - John Helal
- Department of Ophthalmology and Otolaryngology, University of São Paulo Medical School, São Paulo, São Paulo, Brazil
| | - Pedro Carlos Carricondo
- Department of Ophthalmology and Otolaryngology, University of São Paulo Medical School, São Paulo, São Paulo, Brazil
| | - Sérgio Luis Gianotti Pimentel
- Department of Ophthalmology and Otolaryngology, University of São Paulo Medical School, São Paulo, São Paulo, Brazil
| | - Mario Luiz Ribeiro Monteiro
- Department of Ophthalmology and Otolaryngology, University of São Paulo Medical School, São Paulo, São Paulo, Brazil
| | - Cynthia X. Qian
- Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA
- Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, QC, Canada
| | | | | |
Collapse
|
50
|
Daniel E, Aylwin S, Mustafa O, Ball S, Munir A, Boelaert K, Chortis V, Cuthbertson DJ, Daousi C, Rajeev SP, Davis J, Cheer K, Drake W, Gunganah K, Grossman A, Gurnell M, Powlson AS, Karavitaki N, Huguet I, Kearney T, Mohit K, Meeran K, Hill N, Rees A, Lansdown AJ, Trainer PJ, Minder AEH, Newell-Price J. Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. J Clin Endocrinol Metab 2015; 100:4146-54. [PMID: 26353009 PMCID: PMC5393433 DOI: 10.1210/jc.2015-2616] [Citation(s) in RCA: 134] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Cushing's syndrome (CS) is a severe condition with excess mortality and significant morbidity necessitating control of hypercortisolemia. There are few data documenting use of the steroidogenesis inhibitor metyrapone for this purpose. OBJECTIVE The objective was to assess the effectiveness of metyrapone in controlling cortisol excess in a contemporary series of patients with CS. DESIGN This was designed as a retrospective, multicenter study. SETTING Thirteen University hospitals were studied. PATIENTS We studied a total of 195 patients with proven CS: 115 Cushing's disease, 37 ectopic ACTH syndrome, 43 ACTH-independent disease (adrenocortical carcinoma 10, adrenal adenoma 30, and ACTH-independent adrenal hyperplasia 3). MEASUREMENTS Measurements included biochemical parameters of activity of CS: mean serum cortisol "day-curve" (CDC) (target 150-300 nmol/L); 9 am serum cortisol; 24-hour urinary free cortisol (UFC). RESULTS A total of 164/195 received metyrapone monotherapy. Mean age was 49.6 ± 15.7 years; mean duration of therapy 8 months (median 3 mo, range 3 d to 11.6 y). There were significant improvements on metyrapone, first evaluation to last review: CDC (91 patients, 722.9 nmol/L [26.2 μg/dL] vs 348.6 nmol/L [12.6 μg/dL]; P < .0001); 9 am cortisol (123 patients, 882.9 nmol/L [32.0 μg/dL] vs 491.1 nmol/L [17.8 μg/dL]; P < .0001); and UFC (37 patients, 1483 nmol/24 h [537 μg/24 h] vs 452.6 nmol/24 h [164 μg/24 h]; P = .003). Overall, control at last review: 55%, 43%, 46%, and 76% of patients who had CDCs, UFCs, 9 am cortisol less than 331 nmol/L (12.0 μg/dL), and 9 am cortisol less than upper limit of normal/600 nmol/L (21.7 μg/dL). Median final dose: Cushing's disease 1375 mg; ectopic ACTH syndrome 1500 mg; benign adrenal disease 750 mg; and adrenocortical carcinoma 1250 mg. Adverse events occurred in 25% of patients, mostly mild gastrointestinal upset and dizziness, usually within 2 weeks of initiation or dose increase, all reversible. CONCLUSIONS Metyrapone is effective therapy for short- and long-term control of hypercortisolemia in CS.
Collapse
Affiliation(s)
- Eleni Daniel
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Simon Aylwin
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Omar Mustafa
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Steve Ball
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Atif Munir
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Kristien Boelaert
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Vasileios Chortis
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Daniel J Cuthbertson
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Christina Daousi
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Surya P Rajeev
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Julian Davis
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Kelly Cheer
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - William Drake
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Kirun Gunganah
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Ashley Grossman
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Mark Gurnell
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Andrew S Powlson
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Niki Karavitaki
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Isabel Huguet
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Tara Kearney
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Kumar Mohit
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Karim Meeran
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Neil Hill
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Aled Rees
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Andrew J Lansdown
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Peter J Trainer
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - Anna-Elisabeth H Minder
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| | - John Newell-Price
- The Medical School (E.D., J.N.-P.), University of Sheffield, S10 2RX Sheffield, United Kingdom; King's College Hospital NHS Foundation Trust (S.A., O.M.), B15 2TT London, United Kingdom; The Medical School (S.B.), Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary (S.B., A.M.), SE5 9RS Newcastle, United Kingdom; College of Medical and Dental Sciences (K.B., V.C., N.K.), Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Department of Obesity and Endocrinology (D.J.C., C.D., S.P.R.), University of Liverpool, NE1 4LP Liverpool, United Kingdom; Centre for Endocrinology and Diabetes (J.D.), University of Manchester, L69 3GA Manchester, United Kingdom; Manchester Royal Infirmary (K.C.), M13 9WL Manchester, United Kingdom; Department of Endocrinology (W.D., K.G.), St Bartholomew's Hospital, EC1A 7BE London, United Kingdom; Oxford Centre for Diabetes (A.G., N.K., I.H.), Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science (M.G., A.S.P.), University of Cambridge, Addenbrooke's Hospital, OX3 7LE Cambridge, United Kingdom; Salford Royal Foundation Trust (T.K., K.Mo.), CB2 0QQ Salford, United Kingdom; Imperial College (K.Me., N.H.), SW7 2AZ London, United Kingdom; School of Medicine (A.R., A.J.L.), Cardiff University, CF14 4XN Cardiff, United Kingdom; and The Christie NHS Foundation Trust (P.J.T., A.-E.H.M.), M20 4BX Manchester, United Kingdom
| |
Collapse
|